{"study_id": 386, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine how DNMT1-mediated repression of ALDHs and \u03b2-alanine biosynthesis contributes to endothelial dysfunction and atherosclerosis under disturbed flow conditions.", "results_summary": "The study found that disturbed flow-induced endothelial dysfunction was linked to reduced ALDHs and \u03b2-alanine biosynthesis, and supplementation with \u03b2-alanine metabolites (carnosine and acetate) reversed endothelial dysfunction by inhibiting Smad2/3 phosphorylation.", "population_specificity": "Cultured endothelial cells and endothelial lineage tracing mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:36.382203+00:00"}
{"study_id": 384, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine the association between the aspartate transaminase-to-alanine transaminase ratio and metabolic syndrome in HIV patients on antiretroviral therapy.", "results_summary": "The study found a significant association between the aspartate transaminase-to-alanine transaminase ratio and metabolic syndrome, with the ratio also correlating significantly with blood pressure.", "population_specificity": "302 HIV-positive adults on highly active antiretroviral therapy (54.6% female, median age 41 years).", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study conducted from January 15 to June 30, 2021.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:36.664383+00:00"}
{"study_id": 382, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the applicability of alanine/EPR dosimetry systems for routine mailed dose audits of passively scattered therapeutic proton beams in ocular radiotherapy.", "results_summary": "The study found very good agreement between the dose measured by three laboratories using alanine dosimeters and the delivered dose determined with an ionisation chamber, highlighting alanine's suitability for postal auditing in proton ocular radiotherapy due to its favorable properties like tissue equivalence and dose rate independence.", "population_specificity": "Proton therapy facilities (specifically the ocular proton therapy facility at the Cyclotron Centre Bronowice in Krakow).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:36.989385+00:00"}
{"study_id": 379, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the impact of varying ALT level thresholds in identifying significant liver injury among chronic hepatitis B (CHB) patients in the \"grey zone\" phases.", "results_summary": "The study found that 63.7% of GZ CHB patients developed significant hepatic injury (SHI), and lowering ALT treatment thresholds improved the accuracy of identifying patients with significant liver damage. The proportion of patients requiring antiviral therapy increased when using stricter ALT criteria.", "population_specificity": "1617 adult patients diagnosed with chronic hepatitis B (CHB) who underwent liver biopsy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.170174+00:00"}
{"study_id": 383, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine how the inhibition of the mitochondrial pyruvate carrier (MPC) and alanine aminotransferase 2 (ALT2) affects susceptibility to acetaminophen (APAP)-induced liver injury in vivo.", "results_summary": "The study found that MPC inhibition alone did not sensitize the liver to APAP-induced injury, but concomitant loss of ALT2 significantly worsened liver damage by impairing glutathione synthesis and increasing urea cycle flux. ALT2 induction and dichloroacetate treatment reduced APAP-induced liver injury, suggesting potential therapeutic approaches.", "population_specificity": "Mice and cell culture models", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.328168+00:00"}
{"study_id": 385, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to assess the association between low alanine aminotransferase (ALT) levels, indicative of sarcopenia and frailty, and shorter survival in prostate cancer patients and survivors.", "results_summary": "Low ALT (<17 IU/l) was associated with a significant increase in mortality risk (78% higher in univariate analysis, 35% higher in multivariable analysis) among prostate cancer patients and survivors, suggesting its potential as a marker for survival outcomes.", "population_specificity": "Prostate cancer patients and survivors (mean age 74.6 years).", "effective_dosage": "Not applicable (ALT levels were measured, not administered).", "study_duration": "Retrospective analysis (no intervention duration specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.570660+00:00"}
{"study_id": 380, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine how glutathione (GSH) and its degraded amino acids influence the formation of pyrazines and 2,3-butanedione during the thermal treatment of the Amadori compound of alanine and xylose (ARP).", "results_summary": "The study found that GSH and its degraded amino acids (glutamic acid, cysteine, and glycine) enhanced pyrazine formation and interfered with 2,3-butanedione production by consuming deoxypentosones. Exogenous GSH increased yields of both compounds compared to ARP alone.", "population_specificity": "Not specified (in vitro chemical reaction study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:37.772044+00:00"}
{"study_id": 381, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between alanine aminotransferase (ALT) levels and biochemical parameters in women with premature ovarian insufficiency (POI) to assess potential risk factors and liver function implications.", "results_summary": "The study found that ALT levels were significantly higher in POI patients compared to controls and were positively associated with BMI, FSH, UA, AST, MONO, NLR, NEUT, and WBC, while negatively associated with E2. Multiple linear regression confirmed independent positive correlations between AST, FSH, and ALT, suggesting a risk of liver function damage in POI patients.", "population_specificity": "Women with premature ovarian insufficiency (POI) and subclinical POI (n=126) compared to healthy controls (n=130).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:38.382622+00:00"}
{"study_id": 387, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of \u03b2-alanine (ALA) and L-carnosine (CAR) in mitigating hypobaric hypoxia-induced skeletal muscle protein loss.", "results_summary": "ALA supplementation reduced hypoxia-induced inflammation, oxidative stress, ER stress, and atrophic signaling in skeletal muscles, but was less effective than CAR in restoring protein concentration and body weight.", "population_specificity": "Rats exposed to simulated hypobaric hypoxia.", "effective_dosage": "450 mg\u00b7kg\u207b\u00b9 daily", "study_duration": "3 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:45.410035+00:00"}
{"study_id": 391, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to investigate the clinical implications of low ALT activity genotype in diagnosing and managing copper-associated hepatopathy (CuCH) in dogs.", "results_summary": "The study found that a dog with CuCH and a heterozygous low ALT activity gene allele had normal ALT levels despite significant hepatic copper accumulation and mild hepatocellular necrosis, suggesting ALT may not reliably indicate liver injury in such cases.", "population_specificity": "A 9-year-old female spayed Siberian Husky with copper-associated hepatopathy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:46.169837+00:00"}
{"study_id": 393, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to review recent developments and patents related to MARCKS-targeting peptides, including their therapeutic potential for diseases like asthma, cancer, inflammation, and lung diseases.", "results_summary": "The abstract highlights early clinical success of a MARCKS-targeting drug (BIO-11006) and identifies two MARCKS-targeting peptides with potential implications for multiple diseases, but does not specifically discuss Alanine.", "population_specificity": "Not specified (review article, not a clinical study)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:47.367321+00:00"}
{"study_id": 392, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop a semimechanistic pharmacokinetic/pharmacodynamic model to characterize methotrexate-induced hepatotoxicity based on alanine aminotransferase (ALT) levels in pediatric patients with acute lymphoid leukemia.", "results_summary": "The study developed a PK model using MTX concentrations and a PD model using ALT levels, finding that MTX-induced hepatotoxicity could be described by an indirect response model coupled with a liver injury signal transduction model. No significant covariates impacted PD parameters.", "population_specificity": "Pediatric patients with acute lymphoid leukemia.", "effective_dosage": "High-dose MTX (3-5 g/m\u00b2).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:47.688447+00:00"}
{"study_id": 389, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a risk prediction model to individualize laboratory testing for alanine transaminase (ALT) elevations in patients initiating conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).", "results_summary": "The study found that higher baseline ALT, use of csDMARDs other than methotrexate or sulfasalazine, and a psoriatic arthritis diagnosis were predictors of ALT elevations >2\u00d7ULN. The model achieved a concordance index of 0.71-0.72, demonstrating good predictive accuracy.", "population_specificity": "Inflammatory joint disease patients (N=1196) initiating csDMARDs at Turku University Hospital (2013-2019).", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:48.151331+00:00"}
{"study_id": 390, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to estimate the proportions of histological changes (moderate to severe necroinflammation, significant fibrosis, and cirrhosis) among treatment-na\u00efve chronic hepatitis B (CHB) patients within different upper limits of normal (ULNs) for alanine aminotransferase (ALT).", "results_summary": "The study found that significant histological changes occurred in approximately one-third of CHB patients within ALT ULN at 40 IU/L, while the proportion of significant fibrosis was about one-fifth even in those within ALT ULN at 20 IU/L. Subgroup analyses indicated higher fibrosis proportions in studies with prospective designs or older patient populations.", "population_specificity": "Treatment-na\u00efve chronic hepatitis B (CHB) patients with liver biopsies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:48.256882+00:00"}
{"study_id": 394, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine how L-alanine-induced germination of Bacillus subtilis S-2 spores enhances anti-infectious effects in epithelial cells and the role of the gerAA germination receptor in this process.", "results_summary": "L-alanine-induced germination of B. subtilis S-2 spores significantly increased anti-adhesion activity against ETEC in IPEC-J2 cells, reduced inflammatory factors, and promoted autophagy-related protein expression. The gerAA receptor was found essential for these probiotic effects.", "population_specificity": "Intestinal porcine epithelial cells (IPEC-J2) and Caco2 cells.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:48.705723+00:00"}
{"study_id": 388, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the role of alanine aminotransferase (ALT) levels, alongside the FIB-4 index, in predicting hepatocellular carcinoma (HCC) risk in chronic hepatitis B patients treated with nucleos(t)ide analogs.", "results_summary": "Elevated ALT (\u226531 U/L) at 1 year was identified as an independent risk factor for HCC. A combined score (FAL-1) incorporating FIB-4 \u22651.58 and ALT \u226531 U/L effectively stratified HCC risk, with higher scores correlating to significantly increased HCC incidence.", "population_specificity": "472 chronic hepatitis B virus-infected patients without prior HCC history, treated with nucleos(t)ide analogs.", "effective_dosage": "Not specified", "study_duration": "Follow-up included assessments at baseline, 1 year, and up to 10 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:49.374660+00:00"}
{"study_id": 395, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether MARCKS inhibition affects neutrophil \u03b22-integrin activation and signaling, focusing on inside-out and outside-in activation pathways.", "results_summary": "MARCKS inhibition did not significantly affect inside-out \u03b22-integrin activation but reduced ICAM-1/Mn2+-stimulated static adhesion, cell spreading, and \u03b22-integrin clustering, suggesting a role in outside-in activation.", "population_specificity": "Neutrophils (in vitro study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:54.556105+00:00"}
{"study_id": 398, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether the intensity of alanine aminotransferase (ALT) flares during antiviral therapy is associated with the level of hepatitis B surface antigen (HBsAg) decline.", "results_summary": "The study found that ALT flares, particularly severe ones, were associated with greater HBsAg decline and significantly faster times to HBsAg reduction. Severe flares correlated with faster achievement of HBsAg decline >1 log10 IU and HBsAg level <100 IU/mL.", "population_specificity": "201 participants with hepatitis B e antigen-positive or -negative chronic hepatitis B.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:57.328121+00:00"}
{"study_id": 397, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to analyze hepatic pathological characteristics and factors influencing alanine transaminase (ALT) levels in chronic hepatitis B (CHB) patients to determine the optimal ALT threshold for initiating antiviral therapy.", "results_summary": "The study found that significant liver inflammation and fibrosis were present in CHB patients even with normal or mildly elevated ALT levels. The glutamyltransferase-platelet ratio (GPR) improved the accuracy of assessing liver fibrosis under different ALT thresholds.", "population_specificity": "Treatment-na\u00efve CHB patients (median age 38.0 years, 72.9% male) who underwent liver biopsies.", "effective_dosage": "Not specified", "study_duration": "Retrospective data collected from January 2010 to December 2019 (no specific intervention duration mentioned).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.545964+00:00"}
{"study_id": 396, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to determine whether liver stiffness measurement (LSM) could indicate liver inflammation in chronic hepatitis B (CHB) patients with varying upper limits of normal (ULNs) for alanine aminotransferase (ALT).", "results_summary": "The study found that fibrosis-adjusted LSM values significantly increased with liver inflammation severity, demonstrating high diagnostic accuracy for significant (A\u22652) and severe (A=3) inflammation. An LSM-globulin model outperformed individual markers like ALT and AST but was comparable to LSM alone.", "population_specificity": "439 CHB patients, with subgroups based on different ALT ULNs (\u226440 U/L, \u226435/25 U/L for males/females, \u226430/19 U/L for males/females), plus external (n=84) and prospective (n=96) validation groups.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:58.735078+00:00"}
{"study_id": 102156, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore a federated data analytics method to detect unreported cases of pediatric hepatitis by analyzing elevated AST or ALT levels in children.", "results_summary": "The study found no overall increase in elevated AST or ALT levels during the period of interest, except for a localized increase in the Netherlands. The federated data approach was deemed successful for disease surveillance.", "population_specificity": "Children aged 3 weeks to 5 years, with broader data from all age groups.", "effective_dosage": "Not mentioned", "study_duration": "Data analyzed from December 1, 2021, to August 31, 2022, compared to a baseline period (January 1, 2012, to December 31, 2019).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:59.302324+00:00"}
{"study_id": 399, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate whether changes in alanine transaminase (ALT) and aspartate transaminase (AST) levels could serve as sensitive biomarkers for detecting treatment failure in HCV therapy.", "results_summary": "The study found that a rise in ALT or AST after HCV therapy was highly sensitive for detecting treatment failure, with 100% sensitivity for ALT and 98.1% for AST, though specificity was lower (51% and 35.8%, respectively). These biomarkers could reduce costs and complexity in managing HCV.", "population_specificity": "Patients with HCV in Vietnam (SEARCH-1 trial, n = 52) and the UK (STOPHCV1 trial, n = 202).", "effective_dosage": "Not mentioned", "study_duration": "Follow-up at 12 weeks after end of treatment (EOT).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:10:59.840190+00:00"}
{"study_id": 102157, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to examine the impact of antiretroviral therapy (ART) on liver function, particularly focusing on alanine transaminase (ALT) levels, in pregnant women living with HIV (PWLWHIV) with and without pre-eclampsia (PE).", "results_summary": "The study found conflicting results regarding the effect of ART on liver enzymes (including ALT) in PWLWHIV, with some studies showing increases, decreases, or no effect. The impact of ART on liver function in PWLWHIV with PE remains unclear due to contradictory findings.", "population_specificity": "Pregnant women living with HIV (PWLWHIV), with and without pre-eclampsia (PE).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:00.350007+00:00"}
{"study_id": 400, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether alanine racemase (Alr) inhibition by propanoic acid (PA) could effectively treat Helicobacter pylori infection without resistance development.", "results_summary": "PA showed inhibitory effects on H. pylori with a minimum inhibitory concentration (MIC) of 312.5-416.7 \u03bcg/ml, no resistance development after 14 serial passages, and successful eradication in a rat infection model. PA lacked cytotoxicity in tested cell lines and demonstrated broad-spectrum efficacy against other pathogens.", "population_specificity": "H. pylori ATCC 43504, six clinical H. pylori isolates, and a rat infection model.", "effective_dosage": "MIC ranged from 312.5-625 \u03bcg/ml; minimum bactericidal concentration was 625 \u03bcg/ml.", "study_duration": "14 serial passages for resistance testing; duration in rat model not specified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:00.550533+00:00"}
{"study_id": 102158, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to develop a predictive model for ICU admission in Emergency Department patients with upper gastrointestinal bleeding (UGIB), identifying alanine transaminase level as one of the significant predictors.", "results_summary": "The study found that alanine transaminase level, along with other factors, was a significant predictor of ICU admission in UGIB patients. The new predictive model outperformed existing scoring systems in accuracy.", "population_specificity": "Patients with acute upper gastrointestinal bleeding treated at a single tertiary medical center.", "effective_dosage": "Not specified", "study_duration": "Retrospective analysis of data from January 2020 to July 2022.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:04.665479+00:00"}
{"study_id": 102162, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not mention Alanine or its study.", "results_summary": "The abstract does not discuss Alanine or its effects.", "population_specificity": "Not specified (abstract discusses cyanobacteria and cyanotoxins).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:05.611884+00:00"}
{"study_id": 102159, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to analyze clinical characteristics of Mycoplasma pneumoniae infection in children, including the role of alanine aminotransferase as an influencing factor in refractory cases.", "results_summary": "The study found that alanine aminotransferase, along with other biomarkers, was a significant influencing factor in refractory Mycoplasma pneumoniae pneumonia (RMPP). Biochemical treatment involving alanine aminotransferase showed reduced hospital stay and inflammatory markers compared to general treatment.", "population_specificity": "112 children (48 males, 64 females) aged 5.74\u00b12.62 years with Mycoplasma pneumoniae pneumonia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:07.665459+00:00"}
{"study_id": 102166, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of 13 histological liver scores in assessing NAFLD disease activity and evaluate noninvasive biomarkers' ability to reflect these scores.", "results_summary": "The study developed an in silico model to analyze 13 histological features of NAFLD, identifying four disease facets and assessing 69 noninvasive biomarkers for their correlation with these features.", "population_specificity": "914 adults from the NASH-CRN observational NAFLD Database study.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:08.875109+00:00"}
{"study_id": 102163, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to identify risk factors, including liver function markers like alanine aminotransferase, associated with benign central airway stenosis following COVID-19 infection.", "results_summary": "The study found that liver function (measured by alanine aminotransferase and aspartate aminotransferase values) was a risk factor for benign central airway stenosis post-COVID-19 in univariate analysis, but not in multivariate analysis.", "population_specificity": "235 patients hospitalized for COVID-19 infection at the First Affiliated Hospital of Zhengzhou University.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:09.127095+00:00"}
{"study_id": 102165, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate insulin clearance (IC) differences and metabolic phenotypes in youth-onset type 2 diabetes, focusing on sex, race, ethnicity, and treatment effects, but did not specifically study Alanine.", "results_summary": "The study found low IC correlated with female sex, non-Hispanic Black race, and markers of adiposity and insulin resistance, but not with beta cell function. IC increased with rosiglitazone treatment, suggesting it compensates for changes in insulin sensitivity or adiponectin.", "population_specificity": "Youth aged 10-18 years with type 2 diabetes.", "effective_dosage": "Not mentioned", "study_duration": "5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:09.996686+00:00"}
{"study_id": 102167, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to develop a scoring system (STEC-HUSS score) to identify high-risk patients with severe complications of STEC-HUS, not to evaluate Alanine specifically.", "results_summary": "The study found significant differences in laboratory values, including alanine transaminase, between severe and mild STEC-HUS groups, but did not assess Alanine's effects. The STEC-HUSS score effectively identified high-risk patients.", "population_specificity": "Patients with STEC-HUS treated at 11 hospitals in Hokkaido, Japan.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective analysis)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:10.592660+00:00"}
{"study_id": 102161, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of xalnesiran, alone or combined with immunomodulators, in achieving HBsAg loss in patients with chronic HBV infection under virologic suppression.", "results_summary": "Xalnesiran, particularly when combined with pegylated interferon alfa-2a, resulted in HBsAg loss in a substantial percentage of participants (23% in group 4). Adverse events, including elevated alanine aminotransferase levels, were more frequent in combination therapy groups.", "population_specificity": "Participants with chronic HBV infection who had virologic suppression with nucleoside or nucleotide analogue (NA) therapy.", "effective_dosage": "100 mg (group 1), 200 mg (group 2), 200 mg plus 150 mg ruzotolimod (group 3), 200 mg plus 180 \u03bcg pegylated interferon alfa-2a (group 4).", "study_duration": "48 weeks of treatment, with follow-up at 24 weeks post-treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:12.135028+00:00"}
{"study_id": 102168, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the clinical characteristics of human fascioliasis and bacterial liver abscesses, not to evaluate Alanine.", "results_summary": "The study did not investigate Alanine's effects; it focused on differentiating human fascioliasis and bacterial liver abscesses.", "population_specificity": "95 patients with human fascioliasis and 95 with bacterial liver abscesses.", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:13.043361+00:00"}
{"study_id": 102169, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify predictors of probiotics' efficacy on liver-related outcomes, including alanine transferase levels, in subjects with depression and metabolic alterations.", "results_summary": "The study found that probiotics improved alanine transferase levels, particularly in subjects with higher baseline intestinal permeability markers, suggesting liver protection benefits for those with suspected \"leaky gut\" syndrome.", "population_specificity": "92 subjects from a randomized clinical trial on probiotics and depression, likely with comorbid metabolic and liver-related conditions.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:15.172165+00:00"}
{"study_id": 102173, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to analyze the WHO's revised guidelines for chronic hepatitis B management and anticipate areas of agreement or controversy with upcoming liver society guidelines.", "results_summary": "The study discusses the WHO's simplified care and expanded treatment criteria for chronic hepatitis B but does not provide specific findings on Alanine's effects.", "population_specificity": "Not Assessed", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:17.892840+00:00"}
{"study_id": 102170, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the combination of disitamab vedotin (DV) and toripalimab in patients with locally advanced or metastatic urothelial carcinoma (la/mUC), not specifically to assess Alanine.", "results_summary": "The study did not focus on Alanine's effects but reported increased alanine aminotransferase as a common treatment-related adverse event (63.4% incidence, with 7.3% grade 3 or higher).", "population_specificity": "Patients with untreated or chemo-refractory locally advanced or metastatic urothelial carcinoma (la/mUC).", "effective_dosage": "Not applicable (Alanine was not a studied intervention).", "study_duration": "Not applicable (Alanine was not a studied intervention).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:18.194835+00:00"}
{"study_id": 102172, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the efficacy and safety of CDK4/6 inhibitors, including their impact on alanine aminotransferase levels in breast cancer patients.", "results_summary": "The study found that Asian patients were significantly more likely to experience increased alanine aminotransferase levels when treated with CDK4/6 inhibitors, indicating a potential liver-related adverse effect. No direct efficacy outcomes related to alanine were reported.", "population_specificity": "Patients with breast cancer, with specific comparisons between Asian and Western populations.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:18.708902+00:00"}
{"study_id": 102171, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 78, "study_goal": "The researchers aimed to develop and validate a predictive model for insufficient future liver remnant hypertrophy after portal vein embolization, incorporating clinical factors including alanine transaminase (ALT) levels.", "results_summary": "The study identified ALT level as one of three independent clinical factors influencing the prediction model, with an odds ratio of 0.98 (95% CI: 0.97-0.99). The combined model (clinical factors and radiomics) showed improved but non-significant predictive performance.", "population_specificity": "241 consecutive patients from three Swedish centers undergoing portal vein embolization.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:19.196406+00:00"}
{"study_id": 102174, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the relationship between weight loss, liver fat reduction, and changes in liver enzymes, including alanine aminotransferase (ALT), as indicators of metabolic dysfunction-associated steatotic liver disease (MASLD) improvement.", "results_summary": "The study found that weight loss significantly reduced liver fat and normalized ALT levels by 38%, with a strong correlation between changes in liver fat and ALT (r = 0.64). Elevated baseline ALT (>40 IU/L) had a 100% positive predictive value for liver fat reduction.", "population_specificity": "42 participants in the intervention group of the Diabetes Remission Clinical Trial (DiRECT) with baseline MASLD prevalence of 86.4%.", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:22.342967+00:00"}
{"study_id": 102177, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the efficacy of dapagliflozin in reducing liver steatosis among patients with nonalcoholic fatty liver disease (NAFLD).", "results_summary": "Dapagliflozin significantly reduced CAP scores and fatty liver grade in NAFLD patients compared to the control group, with no significant differences in liver stiffness, waist circumference, or alanine transaminase levels between groups. The reduction in CAP was associated with dapagliflozin treatment and changes in BMI.", "population_specificity": "Patients with NAFLD and a CAP score of \u2265252 dB/m, including 13% with type 2 diabetes.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:23.635152+00:00"}
{"study_id": 102175, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to summarize the role of the minor allele of the AGXT gene in the molecular pathogenesis and clinical manifestations of Primary Hyperoxaluria Type 1 (PH1), which involves alanine:glyoxylate aminotransferase (AGT).", "results_summary": "The study found that the minor haplotype of the AGXT gene, while not pathogenic on its own, can influence the pathogenicity of certain mutations or amplify others, affecting symptoms and responsiveness to Vitamin B6 treatment in PH1 patients. It also highlighted the need for personalized medicine approaches due to the lack of specific biomarkers for disease severity.", "population_specificity": "Patients with Primary Hyperoxaluria Type 1 (PH1), an autosomal recessive disorder caused by mutations in the AGXT gene.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:23.868523+00:00"}
{"study_id": 102178, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the efficacy and safety of camrelizumab combined with apatinib in previously treated advanced adrenocortical carcinoma (ACC), not specifically studying Alanine.", "results_summary": "The study found that alanine aminotransferase elevation was one of the most common grade 3-4 treatment-related adverse events, but the abstract does not focus on Alanine's effects.", "population_specificity": "Patients with advanced adrenocortical carcinoma (ACC) who had failed standard treatments.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:24.089459+00:00"}
{"study_id": 102180, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pemafibrate, a PPAR\u03b1 agonist, in improving alanine aminotransferase (ALT) levels and other metabolic markers in patients with MASLD/MASH.", "results_summary": "Pemafibrate significantly improved ALT levels and lipid parameters without increasing creatinine levels, suggesting potential benefits for MASLD/MASH patients. Secondary endpoints included improvements in liver fibrosis markers and liver fat mass, measured via MRI and ultrasound.", "population_specificity": "Patients aged 20-80 years with MASLD/MASH.", "effective_dosage": "0.4 mg/day and 0.2 mg/day of pemafibrate, or fenofibrate.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:29.067100+00:00"}
{"study_id": 102182, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the incidence of adverse clinical outcomes (HCC, cirrhosis, hepatic decompensation) and the effect of antiviral therapy in patients with chronic hepatitis B (CHB) in the indeterminate phase.", "results_summary": "The study found that patients in the indeterminate phase are at risk of developing advanced liver disease and HCC, with an annual HCC incidence rate of 0.32%. Antiviral therapy may reduce HCC risk in high-risk subgroups, though significant heterogeneity across studies limits broader treatment recommendations.", "population_specificity": "Patients with chronic hepatitis B (CHB) in the indeterminate phase.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:29.183553+00:00"}
{"study_id": 102179, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to revisit glyoxylate metabolism in humans, particularly focusing on the role of alanine glyoxylate aminotransferase (AGT) and its implications in primary hyperoxaluria types 1, 2, and 3.", "results_summary": "The study highlighted that glyoxylate metabolism involves multiple organs, not just the liver, which may explain the limited efficacy of RNAi-based therapies like nedosiran in PH2 and PH3. It also emphasized the importance of AGT and GRHPR in glyoxylate detoxification and their genetic mutations in causing hyperoxaluria.", "population_specificity": "Humans with primary hyperoxaluria types 1, 2, and 3.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:29.280777+00:00"}
{"study_id": 102181, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the safety and tolerability of an n-3 PUFA-enriched lipid emulsion (Lipidem) in adult patients with chronic intestinal failure requiring long-term home parenteral nutrition, with a focus on liver function parameters and fatty acid profiles.", "results_summary": "The study found no clinically relevant differences in liver function parameters between the n-3 PUFA-enriched LE and the standard LE, with both remaining within normal ranges. The n-3 PUFA-enriched LE increased EPA and DHA levels in plasma and red blood cells, resulting in a desirable n-3-index (>8) and no evidence of essential fatty acid deficiency.", "population_specificity": "Adult patients with chronic intestinal failure requiring long-term home parenteral nutrition.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Average duration of eight weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:30.660110+00:00"}
{"study_id": 102184, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the comparability of venous and capillary blood samples for measuring routine chemistry analytes, including alanine transaminase.", "results_summary": "The study found excellent comparability between venous and capillary blood samples for most analytes, including alanine transaminase, with 30 of 33 analytes meeting TEa criteria.", "population_specificity": "Adult patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:31.568052+00:00"}
{"study_id": 102183, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and outcomes of a modified Kasai operation combined with autologous bone marrow mononuclear cell (BMMNC) infusion for biliary atresia (BA).", "results_summary": "The study found no complications related to the operation or cell infusion, and the combined treatment may maintain or improve liver function in BA patients.", "population_specificity": "Children with biliary atresia (BA).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Follow-up lasted up to 4.5 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:32.174025+00:00"}
{"study_id": 102185, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and efficacy of intraperitoneal versus extraperitoneal Pringle maneuver using a bulldog clamp in laparoscopic liver resection, not specifically to evaluate alanine.", "results_summary": "The study found no significant differences in liver function indices (ALT, AST, TBIL, ALB) between the two groups post-surgery, but the IPM group had lower CRP levels, faster recovery, and shorter hospital stays.", "population_specificity": "80 patients undergoing laparoscopic liver resection.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:33.025533+00:00"}
{"study_id": 102186, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and effects of baricitinib (4 mg and 2 mg) on alanine aminotransferase (ALT) levels and other biomarkers in patients with rheumatoid arthritis.", "results_summary": "Baricitinib 4 mg significantly increased ALT and creatinine levels, while 2 mg did not show significant changes. Both doses increased LDL-C levels, with 4 mg showing a more severe increase. The 4 mg dose also increased infection risk, but serious adverse events were not significantly different between doses or placebo.", "population_specificity": "Patients with moderate to severe rheumatoid arthritis who had insufficient response to conventional synthetic disease-modifying antirheumatic drugs.", "effective_dosage": "4 mg or 2 mg daily", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:34.515177+00:00"}
{"study_id": 102187, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare liver fibrosis severity between HBeAg-positive chronic hepatitis B (CHB) patients in the indeterminate phase versus the immune-tolerant phase.", "results_summary": "The study found that patients in the indeterminate phase had higher liver fibrosis markers (APRI, FIB-4, liver stiffness) and significantly greater proportions of significant fibrosis and cirrhosis compared to those in the immune-tolerant phase.", "population_specificity": "Treatment-na\u00efve HBeAg-positive CHB patients with normal alanine aminotransferase (ALT) levels.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:38.346315+00:00"}
{"study_id": 102188, "supplement_id": 863, "safety_score": "65", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and preliminary clinical benefit of linperlisib, a PI3K\u03b4 inhibitor, in patients with advanced solid tumors, with a focus on adverse events including changes in alanine aminotransferase (ALT) levels.", "results_summary": "The study found that linperlisib had an acceptable safety profile, with common adverse events including increased ALT (22.3%). Efficacy was limited, with a low objective response rate (1.1%) and modest disease control rate (37.2%).", "population_specificity": "Patients with histologically confirmed advanced solid tumors from eight centers in China.", "effective_dosage": "80 mg/day (oral)", "study_duration": "Median follow-up time was 4.2 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:39.704533+00:00"}
{"study_id": 102189, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the impact of ertugliflozin on improving NAFLD in patients with T2DM, including its effects on liver enzymes like alanine aminotransferase.", "results_summary": "The study found that ertugliflozin significantly improved fatty liver grades and reduced aspartate aminotransferase and alanine aminotransferase levels, particularly in the ertugliflozin group. The treatment showed favorable effects on liver fat intake and complications in NAFLD-associated T2DM patients.", "population_specificity": "Patients with NAFLD and type 2 diabetes mellitus (T2DM).", "effective_dosage": "15 mg of ertugliflozin versus 30 mg of pioglitazone versus placebo.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:40.729076+00:00"}
{"study_id": 102191, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate serum autotaxin levels in hypertensive postmenopausal women and establish its relationship with metabolic and renal comorbidities.", "results_summary": "The study found that serum autotaxin levels were significantly higher in hypertensive postmenopausal women and were positively associated with blood pressure, metabolic disturbances, and impaired renal health. Autotaxin independently predicted hypertension risk after adjusting for demographic and metabolic parameters.", "population_specificity": "Postmenopausal women (25 hypertensive and 25 normotensive controls).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:40.802486+00:00"}
{"study_id": 102192, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness, safety, and potential mechanisms of Traditional Chinese Medicine (TCM) combined with PD-1/PD-L1 inhibitors in cancer animal models.", "results_summary": "The meta-analysis found that TCM + PD-1/PD-L1 inhibitors significantly inhibited tumor growth, reduced tumor weight, prolonged survival time, and enhanced immune function in animal models of various cancers. However, significant heterogeneity among studies warrants caution in interpreting the results.", "population_specificity": "Animal models of colon, breast, colorectal, melanoma, and bladder cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:41.831469+00:00"}
{"study_id": 102190, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the adverse drug reactions (ADRs) of four fast-track COVID-19 drugs, including remdesivir, which was associated with increased alanine aminotransferase levels, using real-world data from the FAERS database.", "results_summary": "The study found that \"increased alanine aminotransferase\" (14.5%) was the most frequently reported serious adverse drug reaction for remdesivir, indicating potential liver-related side effects. No significant safety signals were observed for alanine itself, as the focus was on drug-induced effects.", "population_specificity": "Cases reported to the FDA Adverse Event Reporting System (FAERS) from January 2020 to June 2022, involving patients taking COVID-19 drugs.", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:43.448178+00:00"}
{"study_id": 102193, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to investigate associations between serum cytokines, including IL-15, FGF-9, and HGF, and metabolic markers like alanine aminotransferase (ALT) in overweight/obese adolescents with insulin resistance.", "results_summary": "Higher IL-15, FGF-9, and HGF levels were significantly associated with elevated ALT levels and lower AST/ALT ratios, suggesting potential links between these cytokines and liver-related metabolic dysfunction in insulin-resistant adolescents.", "population_specificity": "Overweight/obese, inactive adolescents aged 11-17 years with insulin resistance (HOMA-IR >2.5).", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (no intervention duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:43.598503+00:00"}
{"study_id": 102194, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the laboratory safety profile of tofacitinib, including alanine aminotransferase levels, in hospitalized COVID-19 pneumonia patients compared to placebo.", "results_summary": "Alanine aminotransferase levels were higher in tofacitinib-treated patients compared to placebo, but no clinically meaningful changes in liver enzymes or hematological parameters were observed.", "population_specificity": "Hospitalized patients with COVID-19 pneumonia (n=289).", "effective_dosage": "Not specified in the abstract.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:44.749594+00:00"}
{"study_id": 102195, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not attempting to determine anything about Alanine; the abstract discusses clinical practice guidelines for chronic hepatitis B virus (HBV) infection.", "results_summary": "The abstract does not mention Alanine or its effects; it focuses on HBV guidelines, treatment thresholds, and benefits of treating more people to avoid complications like HCC.", "population_specificity": "Not specified (abstract discusses general HBV guidelines)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:46.909976+00:00"}
{"study_id": 102198, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of volatile anesthesia (VA) on early clinical outcomes, including alanine transaminase (ALT) levels, in liver transplant recipients.", "results_summary": "VA was associated with a reduced incidence of early allograft dysfunction (EAD) but showed no significant association with postoperative ALT levels or hospitalization time.", "population_specificity": "Liver transplant recipients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:48.825004+00:00"}
{"study_id": 102197, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to assess the predictive performance of alanine aminotransferase (ALT) as a biomarker for short-term worsening in COVID-19 patients.", "results_summary": "Lower values of alanine aminotransferase (ALT) at admission were predictive of worsening in COVID-19 patients, but ALT was not among the top biomarkers independently associated with short-term worsening.", "population_specificity": "Consecutive COVID-19 patients without severe symptoms at admission, from 20 hospitals in Paris during the first waves of COVID-19 in 2020.", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:50.592547+00:00"}
{"study_id": 102200, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the effects of probiotics on gut microbiota regulation in overweight or obese young adults.", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "Overweight or obese young adults (n=75)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:50.651006+00:00"}
{"study_id": 102199, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the effect of an Internet + E-Coach chronic disease system intervention on liver function indicators, including alanine transaminase (ALT), in patients with chronic diabetic retinopathy.", "results_summary": "The study found that ALT levels in the research group were significantly lower than those in the control group after 6 and 12 months of intervention, indicating improved liver function. The intervention also stabilized blood sugar, blood lipid levels, and reduced inflammatory markers.", "population_specificity": "208 patients with chronic diabetic retinopathy.", "effective_dosage": "Not specified.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:51.138972+00:00"}
{"study_id": 102196, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to compare the efficacy and safety of different treatment regimens (including buparlisib, dalpiciclib, fulvestrant, and ribociclib) in postmenopausal women with hormone receptor-positive and HER2-negative breast cancer, with incidental mention of alanine aminotransferase levels as an adverse effect marker.", "results_summary": "Increased levels of alanine aminotransferase were reported as an adverse effect in the RL and BF cohorts, with higher incidence in the BF cohort compared to the DF and RL cohorts. The study did not evaluate alanine as a supplement or its direct effects.", "population_specificity": "Postmenopausal women with hormone receptor-positive and HER2-negative breast cancer.", "effective_dosage": "Not specified for alanine.", "study_duration": "Until unacceptable toxicity was observed (no specific duration provided).", "interactions": "None mentioned for alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:51.774472+00:00"}
{"study_id": 102202, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effect of serum IL-10 levels on clinical outcomes and the incidence of post-COVID-19 pulmonary fibrosis, not specifically Alanine.", "results_summary": "The study found elevated serum IL-10 was associated with COVID-19 pneumonia severity but had an independent role in reducing post-COVID-19 pulmonary fibrosis. No direct findings on Alanine were reported.", "population_specificity": "100 COVID-19 patients (50 with pneumonia, 50 without).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:53.500901+00:00"}
{"study_id": 102201, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of SG001 (an anti-PD-1 monoclonal antibody) in patients with PD-L1-positive recurrent or metastatic cervical cancer, not Alanine.", "results_summary": "The study found that SG001 monotherapy showed durable anti-tumor activity with an objective response rate of 29.0% and acceptable safety in the target population. Common adverse events included leukopenia, increased liver enzymes, and thyroid dysfunction.", "population_specificity": "Patients \u226518 years with PD-L1-positive recurrent or metastatic cervical cancer who had progression on or intolerance to first-line platinum-based chemotherapy.", "effective_dosage": "SG001 240 mg every two weeks.", "study_duration": "Up to 24 months or until disease progression, intolerable toxicities, or other discontinuation criteria were met.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:54.694800+00:00"}
{"study_id": 102205, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "The researchers aimed to review the efficacy, safety, and mechanisms of action of glatiramer acetate (GA), which contains L-alanine, in treating multiple sclerosis (MS).", "results_summary": "GA demonstrated efficacy in reducing relapses and slowing disability accumulation in MS patients, with immunomodulatory and neuroprotective effects, including anti-inflammatory responses, neurotrophic factor secretion, remyelination, and neurogenesis.", "population_specificity": "Patients with multiple sclerosis (MS).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:11:59.887739+00:00"}
{"study_id": 102207, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the impact of metabolic and bariatric surgery (MBS) on liver disease markers, including alanine transaminase (ALT), in adolescents with severe obesity.", "results_summary": "The study found improvements in ALT levels, hepatocyte steatosis, fibrosis, and liver fat content post-MBS, with greater ALT improvements in patients with higher baseline values or advanced steatohepatitis. However, fibrosis did not completely resolve by 12 months post-MBS.", "population_specificity": "Adolescents with severe obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).", "effective_dosage": "Not available", "study_duration": "Up to 12 months post-MBS", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:00.538906+00:00"}
{"study_id": 102206, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to investigate the potential of SNP-630 and SNP-630-MS to alleviate liver injury in MASH by targeting multiple pathways, including reducing ALT levels and improving liver inflammation, steatosis, and fibrosis.", "results_summary": "SNP-630 and SNP-630-MS significantly reduced ALT levels, hepatic triglyceride content, and inflammatory and fibrotic markers in mice. In patients, SNP-630-MS improved ALT levels and showed antifibrotic effects with no severe adverse events.", "population_specificity": "MASH mouse model and 35 patients with MASH.", "effective_dosage": "Not specified in the abstract.", "study_duration": "12 weeks for the clinical trial.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:00.782383+00:00"}
{"study_id": 102208, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of alanine metabolism in the context of probiotic intervention for chronic constipation, as part of broader metabolic pathway analysis.", "results_summary": "The study identified alanine metabolism as one of the pathways associated with probiotic-induced improvements in constipation, alongside changes in gut microbiota and other metabolites. Probiotic treatment altered metabolic pathways, including alanine, aspartate, and glutamate metabolism, suggesting a potential role in symptom relief.", "population_specificity": "Patients with chronic constipation.", "effective_dosage": "Not specified for alanine (probiotic dosage not detailed in abstract).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:01.334265+00:00"}
{"study_id": 102203, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the treatment effects of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB) patients with mild alanine aminotransferase (ALT) elevation.", "results_summary": "The study found that 3-year TDF treatment led to significant histopathological improvements (reduced fibrosis and necroinflammation scores), stable virological and biochemical outcomes, but no change in serum HBsAg levels. Improvements were more pronounced in patients switching from placebo to TDF.", "population_specificity": "Non-cirrhotic patients with chronic hepatitis B and ALT levels below two times the upper limit of normal (median age 47 years, 80.8% male).", "effective_dosage": "Not specified in the abstract.", "study_duration": "3 years (initial randomized intervention) followed by 3 years of open-label TDF.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:02.028274+00:00"}
{"study_id": 102210, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to analyze the effectiveness of Chinese patent medicines, including their impact on Alanine aminotransferase (ALT) levels, in treating NAFLD.", "results_summary": "Huazhi Rougan granules significantly increased ALT levels (96.2%) and improved AST levels, while Danning tablets showed the highest clinical efficacy rate (75.3%) among standalone treatments.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD) in China.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:02.738156+00:00"}
{"study_id": 102209, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and antiviral activity of VIR-2218 (a small interfering RNA agent) with and without pegylated interferon-alpha-2a in participants with chronic HBV infection.", "results_summary": "The study found that VIR-2218 reduced HBsAg concentrations, with most adverse events being mild to moderate. Elevations in alanine aminotransferase were common, particularly in cohorts receiving pegylated interferon-alfa-2a.", "population_specificity": "Adults aged 18-65 with chronic HBV infection, without cirrhosis, predominantly HBeAg-negative, Asian, and male.", "effective_dosage": "VIR-2218 200 mg subcutaneously every 4 weeks; pegylated interferon-alfa-2a 180 \u03bcg subcutaneously once per week (varying doses across cohorts).", "study_duration": "Ranged from 12 to 48 weeks depending on the cohort.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:03.737719+00:00"}
{"study_id": 102212, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to investigate the roles of cytokines and laboratory parameters, including alanine aminotransferase (ALT), in predicting the need for intensive care in COVID-19 patients.", "results_summary": "The study found that elevated ALT levels were significantly associated with the need for intensive care in COVID-19 patients, but it did not assess the efficacy or safety of alanine as a supplement.", "population_specificity": "116 hospitalized COVID-19 patients (74 male, 42 female) with a mean age of 55.3 \u00b1 16.4 years.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:09.417754+00:00"}
{"study_id": 102211, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of BMS-986156 (a GITR agonist) in combination with ipilimumab or nivolumab, with or without stereotactic ablative radiotherapy, in patients with advanced solid cancers.", "results_summary": "BMS-986156 was well-tolerated, with Grade 1-3 treatment-related adverse events reported in 44% of patients, primarily elevated alanine aminotransferase and aspartate aminotransferase. Efficacy analysis showed 48.7% of patients had stable disease and 7.7% achieved a partial response, with the highest abscopal response rates in Group 3 (nivolumab + BMS-986156 + SABR).", "population_specificity": "Patients with histologically-confirmed stage IV solid cancers resistant to standard treatments.", "effective_dosage": "BMS-986156 at 30 mg or 100 mg (dose levels 1 and 2) every 3 weeks with ipilimumab (3 mg/kg), or 30 mg every 4 weeks with nivolumab (480 mg).", "study_duration": "Four cycles (every 3 or 4 weeks depending on group), with maintenance nivolumab possible for up to 2 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:09.710703+00:00"}
{"study_id": 102220, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to diagnose a case of primary hyperoxaluria type 1 (PH1) in an infant presenting with acute renal failure using whole-exome sequencing.", "results_summary": "The study identified a homozygous mutation in the infant, confirming the diagnosis of PH1, which is associated with recurrent renal calculi, renal calcification, and high mortality in infants.", "population_specificity": "An infant with acute renal failure.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:11.241506+00:00"}
{"study_id": 102216, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the long-term effects of febuxostat on arterial stiffness in patients with hyperuricemia, focusing on liver function as indicated by baseline alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels.", "results_summary": "The study found no significant overall difference in arterial stiffness between the febuxostat and control groups at 24 months. However, febuxostat showed a beneficial effect on arterial stiffness in participants with higher baseline ALT or AST levels (\u226530 U/L).", "population_specificity": "Patients with asymptomatic hyperuricemia, some with elevated liver enzymes (ALT or AST \u226530 U/L).", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:11.346560+00:00"}
{"study_id": 102217, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether common biomarker scores, including alanine aminotransferase (ALAT), could help identify severe NAFLD and improve outcomes after OAGB surgery.", "results_summary": "Abnormal ALAT was associated with metabolic risk factors like high triglycerides, blood pressure, and glucose. Patients with higher fibrosis scores showed greater postoperative improvements in body mass, blood pressure, and insulin levels, while those with lower scores had better lipid metabolism but higher glucose concentrations.", "population_specificity": "48 patients who underwent one anastomosis gastric bypass (OAGB) surgery, categorized by ALAT levels, NAFLD fibrosis score, and insulin resistance.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:11.977682+00:00"}
{"study_id": 102213, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the safety and efficacy of maternal tenofovir alafenamide fumarate (TAF) prophylaxis in preventing mother-to-child transmission of hepatitis B virus (HBV-MTCT), including monitoring alanine aminotransferase levels.", "results_summary": "The study found that TAF was well tolerated with no discontinuations due to adverse events, no congenital defects in infants, and normal physical development. Alanine aminotransferase levels were mildly elevated in some women postpartum, but no flares occurred.", "population_specificity": "Pregnant women with HBV DNA levels of 5.3-9.0 log 10 IU/mL.", "effective_dosage": "Not specified (TAF administered from 33 gestational weeks to delivery or 4 weeks postpartum).", "study_duration": "Expected 8 weeks prenatal or 12 weeks total (including postpartum).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:12.594947+00:00"}
{"study_id": 102221, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of the EndoZip device for gastric volume reduction and treatment of obesity, not Alanine.", "results_summary": "The study found that the EndoZip device was safe and effective for treating obesity, leading to weight loss, changes in comorbidities, and improved quality of life.", "population_specificity": "45 patients with a body mass index of 30 to 40 kg/m\u00b2.", "effective_dosage": "Not applicable", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:12.638355+00:00"}
{"study_id": 102219, "supplement_id": 863, "safety_score": "85", "efficacy_score": 78, "quality_score": 82, "study_goal": "The researchers aimed to investigate the clinical efficacy and safety of the Zangsiwei Qingfei Mixture (which includes Alanine transaminase as a safety indicator) combined with conventional treatment in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).", "results_summary": "The study found that the Zangsiwei Qingfei Mixture combined with conventional treatment improved clinical symptoms and promoted homeostasis in AECOPD patients, with no significant adverse effects on liver and kidney function, including Alanine transaminase (ALT) levels.", "population_specificity": "60 AECOPD patients admitted to the Second Xiangya Hospital of Central South University.", "effective_dosage": "Not specified for Alanine transaminase (ALT) as it was a safety indicator, not a treatment component.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:14.953243+00:00"}
{"study_id": 102228, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to compare the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) with and without lipiodol in patients with advanced hepatocellular carcinoma, not specifically focused on Alanine.", "results_summary": "The study found no significant differences in clinical outcomes or adverse events (including alanine aminotransferase elevation) between HAIC with lipiodol and HAIC without lipiodol.", "population_specificity": "85 patients with advanced hepatocellular carcinoma.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:21.290542+00:00"}
{"study_id": 102223, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and activity of a novel combination therapy (decitabine, venetoclax, and ponatinib) in advanced phase Philadelphia chromosome-positive myeloid diseases, not specifically focused on Alanine.", "results_summary": "The study found that the combination therapy showed promising activity (50% complete remission or remission with incomplete recovery) but noted adverse events like alanine transaminase elevation in 25% of patients. The abstract does not focus on Alanine's effects.", "population_specificity": "Patients aged 18+ with advanced phase Philadelphia chromosome-positive myeloid diseases (chronic myeloid leukaemia-blast phase, accelerated phase, or acute myeloid leukaemia).", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "Median follow-up was 21.2 months (IQR 14.1-24.2).", "interactions": "None mentioned (regarding Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:21.805692+00:00"}
{"study_id": 102222, "supplement_id": 863, "safety_score": "40", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to compare the safety and efficacy of evobrutinib (a BTK inhibitor) with teriflunomide in people with relapsing multiple sclerosis, including monitoring liver-related safety markers like alanine aminotransferase levels.", "results_summary": "The study found no superior efficacy of evobrutinib over teriflunomide, with similar annualized relapse rates. However, evobrutinib showed higher rates of liver enzyme elevations (including alanine aminotransferase) and serious adverse events compared to teriflunomide.", "population_specificity": "Adults aged 18-55 with relapsing multiple sclerosis (EDSS score 0.0-5.5).", "effective_dosage": "Evobrutinib (45 mg twice daily) and teriflunomide (14 mg once daily).", "study_duration": "Up to 156 weeks (3 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:21.891658+00:00"}
{"study_id": 102229, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy of probiotics in treating minimum hepatic encephalopathy (MHE), including their impact on alanine aminotransferase levels.", "results_summary": "Probiotic treatment significantly reduced alanine aminotransferase levels (MD\u2009=\u2009-11.10, 95% CI: -16.17 to -6.03, p\u2009<\u2009.0001) and improved liver function in patients with MHE.", "population_specificity": "Patients with minimum hepatic encephalopathy (MHE).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:21.935429+00:00"}
{"study_id": 102227, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the association between environmental toxins, metabolic profiles, and the progression of MASLD to MASH in children, including the role of alanine aminotransferase (ALT) as a marker.", "results_summary": "The study found an inverse association between PFAS/PBDE mixture and MASH, with ALT levels significantly higher in MASH compared to MASLD. Alanine aminotransferase (ALT) was used as a biomarker, but the study did not focus on alanine's therapeutic or dietary effects.", "population_specificity": "435 children (69.9% male) with histologically characterized MASLD or MASH.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:22.359285+00:00"}
{"study_id": 102224, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to assess the safety and recommended phase II dose (RP2D) of ibrutinib and lenalidomide in combination with R-MPV for treating newly diagnosed primary central nervous system lymphoma (PCNSL), including monitoring adverse events like increased alanine aminotransferase levels.", "results_summary": "The study observed two grade 3 increased alanine aminotransferase levels as dose-limiting toxicities, indicating potential hepatic effects. The overall safety profile was consistent with known risks of R-MPV and targeted therapies, with hepatic cytolysis being a frequent adverse event.", "population_specificity": "Patients with newly diagnosed primary central nervous system lymphoma (PCNSL), median age 52.", "effective_dosage": "Not specified for alanine (study focused on ibrutinib and lenalidomide dosages).", "study_duration": "Four 28-day induction cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:23.212911+00:00"}
{"study_id": 102225, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop and validate a prognostic model for hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB) and no notable alanine aminotransferase (ALT) elevation.", "results_summary": "The study found that baseline HBV DNA level was a strong predictor of HCC development, showing a nonlinear parabolic association in both derivation and validation cohorts. The new prognostic model effectively predicted and stratified HCC risk in noncirrhotic CHB patients not currently indicated for antiviral treatment.", "population_specificity": "Noncirrhotic adult patients with chronic hepatitis B (CHB) and no notable alanine aminotransferase (ALT) elevation from community-based and hospital-based cohorts in Taiwan, Korea, and Hong Kong.", "effective_dosage": "Not mentioned", "study_duration": "Median follow-up periods of 10.0 and 12.2 years for derivation and validation cohorts, respectively.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:24.378164+00:00"}
{"study_id": 102230, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the effectiveness of Indocyanine Green (ICG) fluorescence imaging versus conventional fiber-optic imaging in laparoscopic cholangiography and stone removal, not specifically focused on Alanine.", "results_summary": "The study did not focus on Alanine's effects but noted no statistically significant differences in postoperative serum alanine aminotransferase levels between the ICG and control groups.", "population_specificity": "72 patients undergoing laparoscopic bile duct exploration and stone removal (26 males, 46 females).", "effective_dosage": "Not mentioned (study focused on ICG administration, not Alanine).", "study_duration": "Not mentioned (study focused on surgical intervention, not Alanine).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:25.568741+00:00"}
{"study_id": 102231, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to compare the therapeutic efficacy and safety of Ainuovirine (ANV) versus Efavirenz (EFV) in people living with HIV-1.", "results_summary": "ANV and EFV showed similar viral inhibitory effects, but ANV demonstrated better immune reconstitution (CD4/CD8 ratio restoration), improved lipid profiles, and fewer adverse events.", "population_specificity": "People living with HIV-1 (199 in ANV group, 202 in EFV group).", "effective_dosage": "Not specified (ANV/lamivudine/tenofovir vs. EFV/lamivudine/tenofovir).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:31.321626+00:00"}
{"study_id": 102235, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy of Alanine (LRa05) in improving a specific outcome, though the exact goal is not fully detailed in the abstract.", "results_summary": "The LRa05 group showed a trend toward higher performance, but it did not significantly improve the success rate of the measured outcome.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:31.348081+00:00"}
{"study_id": 102232, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify markers associated with liver fibrosis in adults with ZZ alpha-1-antitrypsin deficiency (AATD), including the role of serum Z alpha-1 antitrypsin (AAT) polymer levels.", "results_summary": "Elevated AST, high BMI, obesity, and serum Z AAT polymer levels were associated with increased liver fibrosis. Liver biopsy features correlated with some serum tests, suggesting serum Z AAT polymer could be a future biomarker for fibrosis.", "population_specificity": "96 homozygous ZZ AATD adults at three US sites.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:32.160241+00:00"}
{"study_id": 102233, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and therapeutic efficacy of newer RNAi therapies (olezarsen, plozasiran, and zodasiran) in managing hypertriglyceridemia and mixed hyperlipidemia, including their effects on alanine aminotransferase.", "results_summary": "Plozasiran increased alanine aminotransferase and HbA1c more than placebo at 24 weeks, but the difference was insignificant at 48 weeks. The study did not focus on alanine as a supplement but noted its transient elevation with plozasiran.", "population_specificity": "Patients with hypertriglyceridemia or mixed hyperlipidemia.", "effective_dosage": "Not specified for alanine.", "study_duration": "Up to 48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:33.006444+00:00"}
{"study_id": 102234, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers evaluated hepatotoxicity in two novel regimens (levofloxacin-based and bedaquiline-based) compared to the WHO shorter regimen for rifampicin-resistant tuberculosis, with a focus on alanine aminotransferase levels as a marker of liver injury.", "results_summary": "Hepatotoxicity was significantly higher in the WHO shorter regimen group (26.7%) compared to the levofloxacin (4.7%) and bedaquiline (5.7%) groups. Median peak alanine aminotransferase levels were 1.67 \u00d7 ULN for WHO, 0.82 \u00d7 ULN for levofloxacin, and 0.88 \u00d7 ULN for bedaquiline groups.", "population_specificity": "Patients with rifampicin-resistant tuberculosis (429 participants).", "effective_dosage": "Not specified", "study_duration": "Until treatment ended (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:33.555366+00:00"}
{"study_id": 102238, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were attempting to determine the effectiveness of sintilimab (a PD-1 antibody) in combination with immunochemotherapy as a frontline treatment for primary central nervous system lymphoma (PCNSL).", "results_summary": "The abstract does not provide results regarding Alanine's effects, as the study focuses on sintilimab and immunochemotherapy for PCNSL.", "population_specificity": "Patients aged 18-70 with newly diagnosed primary central nervous system lymphoma (PCNSL).", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Six 21-day cycles (total 126 days).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:33.982434+00:00"}
{"study_id": 102237, "supplement_id": 863, "safety_score": "40", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of ESK981, a tyrosine kinase and PIKfyve lipid kinase inhibitor, in patients with androgen receptor-positive metastatic castration-resistant prostate cancer (mCRPC).", "results_summary": "ESK981 showed minimal anti-tumor activity, with only 7.7% of patients achieving a 50% reduction in PSA levels. Common grade 3 adverse events included alanine transaminase elevations, but no severe (grade 4-5) events occurred.", "population_specificity": "Patients with AR+ mCRPC who had progressed on AR-targeted agents and had no prior chemotherapy.", "effective_dosage": "160 mg once daily for 5 days per week for 4 weeks per cycle.", "study_duration": "4 weeks per cycle (with some patients receiving up to 12 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:35.268408+00:00"}
{"study_id": 102239, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and monitoring requirements for alanine aminotransferase (ALT) levels in patients undergoing gene therapy for hemophilia A.", "results_summary": "The study found that ALT levels above the upper limit of normal (ULN) contraindicate gene therapy, and close monitoring is required post-treatment to detect and manage ALT elevations, which may necessitate immunosuppressant therapy. Elevated ALT levels can be resolved without long-term liver damage if promptly treated.", "population_specificity": "Patients with hemophilia A undergoing gene therapy.", "effective_dosage": "Not specified for alanine; prednisone 60 mg/d for 2 weeks was used for ALT elevation management.", "study_duration": "Monitoring continued for at least one year post-therapy, with long-term follow-up every 3-6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:37.276186+00:00"}
{"study_id": 102240, "supplement_id": 863, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "Oral semaglutide significantly improved body weight, liver enzymes, lipid profile, and glycaemic control, and reduced liver steatosis and fibrosis markers. Adverse events were mostly mild gastrointestinal symptoms.", "population_specificity": "Patients with MASLD and T2DM.", "effective_dosage": "Dose adjustments determined by physicians (not specified).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:40.314347+00:00"}
{"study_id": 102241, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and efficacy of raltitrexed and irinotecan as a second-line treatment for metastatic colorectal cancer, not specifically studying alanine.", "results_summary": "The study reported increased alanine aminotransferase as a common adverse event, but it was mostly Grade I/II and relieved after symptomatic treatment. No specific results regarding alanine's effects were discussed.", "population_specificity": "Patients aged 18-75 with locally advanced or metastatic colorectal cancer after failure of 5-FU and oxaliplatin therapy.", "effective_dosage": "Not specified for alanine.", "study_duration": "Median follow-up was 27 months; intervention duration not explicitly stated.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:41.555665+00:00"}
{"study_id": 102243, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of anlotinib targeted therapy combined with conventional treatment for advanced digestive system neoplasms (DSNs).", "results_summary": "The combination of anlotinib and conventional treatment significantly improved 6-month overall survival and progression-free survival compared to conventional treatment alone, but increased rates of hypertension, albuminuria, and hand-foot syndrome.", "population_specificity": "Patients with advanced digestive system neoplasms (DSNs) (1,613 participants across 20 trials).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:41.864071+00:00"}
{"study_id": 102244, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the clinical features of overweight patients with AECOPD, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "The study found that ALT levels were higher in overweight AECOPD patients compared to normal-weight patients, suggesting a potential metabolic link. No direct effects or outcomes related to alanine supplementation were assessed.", "population_specificity": "Overweight and normal-weight patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:42.548361+00:00"}
{"study_id": 102245, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to explore the efficacy and safety of camrelizumab plus apatinib in patients with previously treated endometrial cancer, not specifically Alanine.", "results_summary": "The study found that camrelizumab plus apatinib showed promising antitumor activity with manageable toxicity, but Alanine was only mentioned as an adverse event (elevated alanine aminotransferase in 16.7% of patients).", "population_specificity": "Patients with advanced or recurrent endometrial cancer who had failed at least one prior systemic therapy.", "effective_dosage": "Not applicable (Alanine was not a treatment component).", "study_duration": "Median follow-up of 14.2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:43.830582+00:00"}
{"study_id": 102242, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-06952229, a TGF-\u03b2 receptor 1 inhibitor, in preclinical and clinical settings.", "results_summary": "PF-06952229 showed antitumor activity in preclinical models and was generally well tolerated in humans, with manageable toxicity. A small subset of patients achieved durable responses or disease stabilization, including one partial response in prostate cancer.", "population_specificity": "Patients aged \u226518 years with advanced/metastatic solid tumors (Part 1A) or metastatic castration-resistant prostate cancer (Part 1B).", "effective_dosage": "20-500 mg oral b.i.d., 7 days on/7 days off, 28-day cycles (Part 1A); 250/375 mg with enzalutamide (Part 1B).", "study_duration": "28-day cycles (duration not specified beyond this).", "interactions": "Combination therapy with enzalutamide was studied (Part 1B).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:44.775366+00:00"}
{"study_id": 102246, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to identify predictors of haemodialysis need in rhabdomyolysis patients, including the role of alanine transaminase (ALT) as a potential marker.", "results_summary": "The study found that ALT levels were significantly associated with the need for haemodialysis in univariate regression analysis, but not in multivariate analysis, where only base excess (BE) was a significant predictor.", "population_specificity": "Patients with rhabdomyolysis (CK >1000 U/L) transferred from an earthquake region.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:45.680429+00:00"}
{"study_id": 102249, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were not directly studying Alanine; the abstract focuses on comparing the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus placebo plus endocrine therapy in HR+/HER2- advanced breast cancer.", "results_summary": "The abstract does not specifically address Alanine's effects; it mentions increased alanine aminotransferase (5.91%) as one of the top grade 3-5 adverse events in the CET group.", "population_specificity": "Individuals with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:47.012016+00:00"}
{"study_id": 102250, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the impact of camu-camu (CC) on hepatic steatosis and metabolic/gut microbiota changes, including effects on alanine aminotransferase levels.", "results_summary": "CC treatment reduced liver fat by 7.43% (vs. an 8.42% increase with placebo) and lowered plasma alanine aminotransferase levels, suggesting potential benefits for liver health. It also altered gut microbiota composition.", "population_specificity": "30 adults with overweight and hypertriglyceridemia", "effective_dosage": "1.5 g of CC capsules daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:49.690989+00:00"}
{"study_id": 102253, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the relationship between multiparametric US imaging markers (DS, AC, SWS) and liver histopathologic necroinflammation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "The study found that lobular inflammation was associated with shear-wave dispersion slope (DS) in patients with MASLD, but the abstract does not mention specific findings related to Alanine.", "population_specificity": "Patients with biopsy-proven MASLD (mean age 53 years \u00b1 15; 62 males).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:51.024079+00:00"}
{"study_id": 102251, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the long-term efficacy and safety of pembrolizumab and cabozantinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC), including correlative biomarker analysis.", "results_summary": "The study found prolonged disease control and survival with pembrolizumab and cabozantinib, with manageable adverse events such as hypothyroidism and elevated liver enzymes. Baseline tumor p-MET expression and immune cell density correlated with improved outcomes.", "population_specificity": "Patients with recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up of 22.4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:52.554399+00:00"}
{"study_id": 102254, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the overall effects of algae and its extracts, including Alanine, on various health outcomes through a systematic review of clinical evidence.", "results_summary": "The study found that algae and its extracts, including Alanine, significantly improved metabolic and cardiovascular health markers such as body weight, BMI, lipid profiles, blood glucose, blood pressure, and liver enzymes. No benefits were observed for inflammation and oxidative stress markers due to limited studies.", "population_specificity": "Not specified (general population inferred from umbrella review of multiple studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:52.914519+00:00"}
{"study_id": 102257, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the real-world systemic adverse event risks of three anti-VEGF agents (bevacizumab, ranibizumab, and aflibercept) in patients with age-related macular degeneration (AMD), including monitoring changes in alanine transaminase levels.", "results_summary": "The study found no significant differences in long-term changes of alanine transaminase levels among the three anti-VEGF agents, indicating comparable systemic safety profiles. All groups showed low and similar risks of systemic adverse events.", "population_specificity": "Individuals aged >50 years with AMD in Taiwan (2014\u20132019).", "effective_dosage": "Not specified", "study_duration": "Retrospective cohort study spanning 2014\u20132019 (exact intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:54.174415+00:00"}
{"study_id": 102259, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the association between tazobactam/piperacillin or meropenem and liver injury, including the role of alanine aminotransferase as a risk factor.", "results_summary": "The study found that male sex, administration period \u22657 days, and elevated alanine aminotransferase were significant risk factors for liver injury in ICU patients receiving tazobactam/piperacillin or meropenem.", "population_specificity": "Intensive care unit (ICU) patients receiving tazobactam/piperacillin or meropenem.", "effective_dosage": "Not specified", "study_duration": "Administration period \u22657 days was a significant risk factor.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:55.227106+00:00"}
{"study_id": 102258, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of IBI351, a KRAS G12C inhibitor, in patients with NSCLC harboring the KRAS G12C mutation.", "results_summary": "IBI351 demonstrated a confirmed objective response rate of 49.1% and a disease control rate of 90.5%, with manageable safety, though 41.4% of patients experienced grade 3 or higher treatment-related adverse events, including increased alanine aminotransferase.", "population_specificity": "Patients with NSCLC and KRAS G12C mutation who failed standard therapy, including prior anti-PD-1/PD-L1 inhibitors and platinum-based chemotherapy.", "effective_dosage": "600 mg twice daily", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:56.104148+00:00"}
{"study_id": 102260, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to identify early acute necrotizing encephalopathy (ANE) in pediatric SARS-CoV-2 cases and evaluate the efficacy of tocilizumab in treatment, not specifically focused on alanine.", "results_summary": "Elevated alanine aminotransferase levels were observed in six patients, indicating potential liver involvement, but the study did not assess alanine's therapeutic effects or safety.", "population_specificity": "Pediatric patients with SARS-CoV-2-associated ANE (n=19, including 8 from Xi'an Children's Hospital).", "effective_dosage": "Not specified for alanine.", "study_duration": "Not specified for alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:12:56.640320+00:00"}
{"study_id": 102261, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the efficacy and safety of pemafibrate (not Alanine) in Chinese patients with hypertriglyceridemia and low HDL-C levels compared to placebo and fenofibrate.", "results_summary": "Pemafibrate significantly reduced triglyceride levels and improved HDL-C, remnant cholesterol, and apolipoprotein A1 levels compared to placebo, with better hepatic and renal safety profiles than fenofibrate.", "population_specificity": "Chinese patients with high triglyceride and low HDL-C levels.", "effective_dosage": "Pemafibrate 0.2 mg/d and 0.4 mg/d, fenofibrate 200 mg/d.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:00.960760+00:00"}
{"study_id": 102262, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine whether probiotic supplementation, including Lactobacillus helveticus and Bifidobacterium longum, influenced liver steatosis and fibrosis markers (including ALT and ALT/AST ratio) in patients with depressive disorders.", "results_summary": "The probiotics did not significantly affect liver steatosis and fibrosis parameters overall, but subgroup analyses showed better improvement in steatosis indices for depressive episode patients and ALT-based indices for antidepressant-treated subjects.", "population_specificity": "Adult patients with depressive disorders (n=92 analyzed).", "effective_dosage": "Not specified for Alanine; probiotic preparation contained Lactobacillus helveticus Rosell\u00ae-52 and Bifidobacterium longum Rosell\u00ae-175.", "study_duration": "60 days.", "interactions": "Better improvement in ALT-based indices noted in antidepressant-treated subjects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:01.433332+00:00"}
{"study_id": 102267, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were attempting to determine the effectiveness of short-term mobile interventions combined with partial meal replacement in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "The abstract does not provide specific results regarding Alanine's effects.", "population_specificity": "Sixty adults with MASLD and a body mass index \u226525 kg/m\u00b2.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:01.572352+00:00"}
{"study_id": 102263, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether genetic markers related to alanine (specifically the valine-arginine-alanine haplotype) and other factors were associated with treatment response in rheumatoid arthritis patients.", "results_summary": "The study found no significant differences in treatment response across subgroups, including those with the valine-arginine-alanine haplotype, for any biological treatment at 48 weeks. Alanine-related genetic markers did not strengthen associations with clinical responses.", "population_specificity": "Treatment-na\u00efve early rheumatoid arthritis patients.", "effective_dosage": "Not specified for alanine.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:02.155338+00:00"}
{"study_id": 102266, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate changes in plasma C15:0 levels after daily supplementation and assess safety, tolerability, and potential markers of physiologic response in young adults with overweight or obesity.", "results_summary": "Daily C15:0 supplementation increased circulating C15:0 levels, and end-of-treatment levels >5 \u03bcg/mL were associated with potentially relevant improvements in clinical indices.", "population_specificity": "Young adults with overweight or obesity (mean age 20.0 \u00b1 2.1 y, mean BMI 33.4 \u00b1 5.3 kg/m\u00b2).", "effective_dosage": "200 mg C15:0 daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:02.168497+00:00"}
{"study_id": 102268, "supplement_id": 863, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the tolerability, safety, and antitumor activity of APG-1387 (a small-molecule inhibitor) alone and in combination with toripalimab for advanced solid tumors.", "results_summary": "APG-1387 monotherapy showed minimal toxicity (one grade \u22653 TRAE of alanine aminotransferase elevation) but no objective responses. The combination with toripalimab had a higher disease control rate (54.5%) and one complete response, though with some grade \u22653 TRAEs.", "population_specificity": "Adults (\u226518 years) with histologically confirmed advanced solid tumors refractory to standard care.", "effective_dosage": "45 mg weekly (RP2D for combination therapy).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:06.010737+00:00"}
{"study_id": 102269, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of fecal microbiota transplantation in treating COVID-19, including its effects on biomarkers like the AST/ALT ratio, which involves alanine aminotransferase (ALT).", "results_summary": "The study found that fecal microbiota transplantation significantly reduced the AST/ALT ratio (a biomarker for long COVID-19) and improved diarrhoea and depressive symptoms in COVID-19 patients. The number of patients with diarrhoea decreased from 19 to 0 by day 7 post-treatment.", "population_specificity": "40 COVID-19 patients with mild-moderate symptoms.", "effective_dosage": "Not specified", "study_duration": "7 days (follow-up period)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:06.229809+00:00"}
{"study_id": 102270, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify potential biomarkers, including alanine aminotransferase (ALT), associated with NAFLD/NASH diagnosis and treatment response to ACC inhibition.", "results_summary": "The study found that 69 analytes, including ALT, correlated with clinical measures of hepatic inflammation and steatosis, with 27 significantly reversed by ACC inhibition. Clesacostat treatment also showed alignment between reduced steatosis probability scores and MRI-PDFF results.", "population_specificity": "Patients with NAFLD/NASH (n=231 baseline, n=72 on-treatment).", "effective_dosage": "25 mg PF-05221304 (Clesacostat).", "study_duration": "Weeks 12 and 16.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:07.035713+00:00"}
{"study_id": 102276, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical efficacy of continuous blood purification (CBP) in children with sepsis, including its effects on alanine transaminase (ALT) levels.", "results_summary": "CBP significantly reduced ALT levels (WMD = -44.867) and improved organ function, immune markers, and inflammatory markers in children with sepsis.", "population_specificity": "Children with sepsis.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:10.226606+00:00"}
{"study_id": 102274, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to assess the presentation and outcome of autoimmune hepatitis (AIH) after 1 year of treatment, focusing on biochemical response, including alanine aminotransferase (ALT) normalization.", "results_summary": "After 12 months of treatment, 63% of patients achieved complete biochemical response (CBR), defined as normalization of ALT and IgG levels, but only 27% achieved steroid-free CBR. Younger age, severe fibrosis, and treatment changes within 6 months were associated with lower chances of ALT normalization.", "population_specificity": "231 patients with autoimmune hepatitis from six European centers.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:11.594336+00:00"}
{"study_id": 102273, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effectiveness of berberine (BBR) in addressing factors linked to metabolic dysfunction-associated fatty liver disease (MAFLD), including its impact on alanine transaminase (ALT) levels.", "results_summary": "The BBR group showed a statistically significant decrease in ALT and de Ritis ratio compared to the placebo group, along with improvements in total cholesterol. However, no significant differences were observed in other lipid and glucose parameters. Correlations were found between changes in BMI, trunk fat, and liver-related indices in the BBR group.", "population_specificity": "Seventy individuals with MAFLD.", "effective_dosage": "1500 mg/day of BBR.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:11.725813+00:00"}
{"study_id": 102275, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to identify risk factors for Hepatitis E (HE) infection, including the role of liver function indicators like alanine aminotransferase (ALT), but did not specifically investigate alanine as a supplement.", "results_summary": "The study found that HE patients had significantly elevated ALT levels (average 621.94 U/L), with severe cases showing even higher levels (1443.81 U/L), indicating liver damage, but did not assess alanine's effects as a supplement.", "population_specificity": "442 HE cases and 428 healthy controls in Zhejiang Province, China.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:12.118673+00:00"}
{"study_id": 102272, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the diagnostic performance of vibration-controlled transient elastography (VCTE) for detecting significant liver fibrosis in antiviral treatment-na\u00efve chronic hepatitis B (CHB) patients with serum alanine transaminase (ALT) levels within 5-fold the upper limit of normal.", "results_summary": "The meta-analysis found that VCTE had acceptable diagnostic performance for significant liver fibrosis (\u2265F2), with summary sensitivity of 0.78 and specificity of 0.72. The optimal cutoff value was 7.7 kPa, yielding a sensitivity of 0.64 and specificity of 0.83.", "population_specificity": "Antiviral treatment-na\u00efve chronic hepatitis B (CHB) patients with ALT levels within 5-fold the upper limit of normal.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:12.507292+00:00"}
{"study_id": 102278, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the antitumor activity of targeted agents, including palbociclib, in patients with advanced cancer and specific genomic alterations.", "results_summary": "The study found that palbociclib met prespecified criteria for antitumor activity in patients with sarcoma, but no specific results related to Alanine were reported.", "population_specificity": "Patients with advanced cancer, specifically soft tissue sarcoma, and genomic alterations known to be drug targets.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:15.184150+00:00"}
{"study_id": 102277, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of two doses (960 mg and 240 mg) of sotorasib in treating KRAS G12C-mutated advanced NSCLC.", "results_summary": "The 960 mg dose showed numerically higher objective response rate (32.7%) and disease control rate (86.5%) compared to the 240 mg dose (24.8% and 81.9%, respectively). Median progression-free survival and overall survival were similar between doses, with manageable treatment-emergent adverse events.", "population_specificity": "Adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).", "effective_dosage": "960 mg once daily and 240 mg once daily.", "study_duration": "Median follow-up of 17.5 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:16.591346+00:00"}
{"study_id": 102279, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of 48-week bulevirtide treatment on health-related quality of life (HRQoL) in patients with chronic hepatitis delta (CHD).", "results_summary": "Patients receiving 2 mg bulevirtide reported significant improvements in HRQoL domains such as role physical, hepatitis-specific limitations, and hepatitis-specific health distress compared to controls. The 10 mg group showed numerically higher scores in some domains, and fatigue levels remained stable across all groups.", "population_specificity": "Patients with chronic hepatitis delta (CHD) and compensated liver disease, stratified by cirrhosis status.", "effective_dosage": "2 mg/day and 10 mg/day", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:16.599657+00:00"}
{"study_id": 102280, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the effects of pemvidutide, a GLP-1/glucagon dual receptor agonist, on liver fat content and metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "Pemvidutide significantly reduced liver fat content, markers of hepatic inflammation, and body weight compared to placebo in patients with MASLD. The study suggests pemvidutide may be effective for treating both metabolic dysfunction-associated steatohepatitis and obesity.", "population_specificity": "Patients with a BMI \u226528.0 kg/m\u00b2 and metabolic dysfunction-associated steatotic liver disease (MASLD).", "effective_dosage": "Not specified (once-weekly treatment).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:20.526017+00:00"}
{"study_id": 102282, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were assessing the potential protective effect of rosuvastatin against chemotherapy-induced cardiotoxicity, with Alanine aminotransferase (ALT) as one of the biomarkers measured.", "results_summary": "The study measured ALT levels but did not report specific findings related to Alanine's effects; the focus was on rosuvastatin's impact on cardiotoxicity biomarkers.", "population_specificity": "50 newly diagnosed HER2-positive breast cancer patients.", "effective_dosage": "Not specified for Alanine.", "study_duration": "6 months (follow-up period).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:20.886764+00:00"}
{"study_id": 102284, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the impact of growth hormone (GH) augmentation on liver steatosis and enzyme levels, including alanine aminotransferase, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "GH augmentation significantly reduced alanine aminotransferase levels (MD: -5.97; 95% CI: -10.31, -1.62; P = 0.007) and improved liver steatosis, but did not significantly affect other metabolic parameters like hemoglobin A1c or triglycerides.", "population_specificity": "Patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:23.134085+00:00"}
{"study_id": 102281, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness and safety of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in treating HBeAg-positive chronic HBV infection, particularly focusing on alanine aminotransferase normalization and renal function.", "results_summary": "TAF showed superior efficacy in HBeAg loss (22.4% vs. 11.2%), antiviral response (65% vs. 54.5%), and alanine aminotransferase normalization (93.9% vs. 81.2%) compared to TDF, with better renal safety. No significant differences were found in HBeAg seroconversion, adverse events, or HBsAg concentration reduction.", "population_specificity": "Patients with HBeAg-positive chronic HBV infection visiting the Liver Clinic at University Medical Center Ho Chi Minh City (2018\u20132020).", "effective_dosage": "Not specified", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:24.045310+00:00"}
{"study_id": 102283, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of cilofexor, a selective farnesoid X receptor agonist, in patients with compensated cirrhosis due to primary sclerosing cholangitis, with exploratory measures including cholestasis and fibrosis markers.", "results_summary": "The study found that cilofexor was well tolerated, with common adverse events like pruritus, fatigue, and headache. It significantly improved cholestasis markers, including reductions in alanine transaminase, alkaline phosphatase, and \u03b3-glutamyl transferase.", "population_specificity": "Patients with compensated cirrhosis due to primary sclerosing cholangitis (median age: 48 years; 55% men).", "effective_dosage": "Escalating doses of 30 mg (weeks 1-4), 60 mg (weeks 5-8), and 100 mg (weeks 9-12) administered orally once daily.", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:24.214671+00:00"}
{"study_id": 102287, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate racial differences in serological markers, including alanine transaminase, in individuals with spinal cord injury across the first year of injury.", "results_summary": "White individuals had higher alanine transaminase levels compared to Black individuals, but the study did not assess the efficacy or safety of alanine itself.", "population_specificity": "316 participants (247 White, 69 Black) with spinal cord injury.", "effective_dosage": "Not available", "study_duration": "Assessments at admission, weeks 1, 2, 4, 8, and 52 post-injury.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:25.689996+00:00"}
{"study_id": 102286, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether probiotic supplementation could improve alanine transaminase levels and insulin sensitivity in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "Probiotic supplementation significantly improved alanine transaminase levels and insulin sensitivity (measured by HOMA-IR) in NAFLD patients, with statistically significant results. The meta-analysis included 15 randomized clinical trials, supporting the efficacy of probiotics in this context.", "population_specificity": "Patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:25.941196+00:00"}
{"study_id": 102285, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers compared the safety and efficacy of drug-eluting bead TACE (DEB-TACE) versus conventional TACE (cTACE) in patients with unresectable hepatocellular carcinoma (HCC) and bile duct invasion after biliary drainage.", "results_summary": "DEB-TACE showed longer time to progression (8.9 vs. 6.7 months) and higher objective response rate (64.2% vs. 39.6%) compared to cTACE, with fewer post-procedural liver toxicity markers and serious adverse events. Overall survival was similar between groups.", "population_specificity": "Patients with unresectable HCC and B1-type bile duct invasion (B1-BDI) after successful biliary drainage.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:26.434423+00:00"}
{"study_id": 102289, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess factors contributing to morbidity and mortality in cases of acute paraphenylenediamine poisoning, with a focus on hepatic and cardiac toxicity, including the role of alanine aminotransferase activity.", "results_summary": "Elevated alanine aminotransferase activity (>798 IU/L) was associated with increased morbidity and mortality in acute paraphenylenediamine poisoning, but the study did not evaluate alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with acute paraphenylenediamine poisoning presenting to Sohag University Hospitals.", "effective_dosage": "Not available", "study_duration": "Retrospective (February 2021 to January 2022) and prospective (February 2022 to July 2022) components.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:31.084123+00:00"}
{"study_id": 102291, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize the clinical and biological features of dengue-associated liver involvement, including the role of elevated Alanine Aminotransferase (ALT) as a diagnostic marker.", "results_summary": "Elevated Alanine Aminotransferase (ALT) levels were prevalent in dengue-associated liver involvement, indicating liver damage, but the study did not assess the efficacy or safety of alanine supplementation.", "population_specificity": "Patients with dengue-associated liver involvement, predominantly males and older adults.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:32.596615+00:00"}
{"study_id": 102288, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers assessed the efficacy and safety of encorafenib plus binimetinib in patients with BRAFV600-mutant melanoma and brain metastasis, exploring whether radiotherapy improves response duration.", "results_summary": "The study found that encorafenib plus binimetinib showed promising clinical benefit with a 70.8% intracranial response rate and tolerable safety, though increased alanine aminotransferase (ALT) was a common grade 3-4 adverse event. Sequential radiotherapy was feasible but did not significantly prolong response.", "population_specificity": "Patients with BRAFV600-mutant melanoma and brain metastasis, including those with symptoms and corticosteroid use.", "effective_dosage": "Encorafenib 450 mg once daily plus binimetinib 45 mg BID.", "study_duration": "Treatment continued until progression (median intracranial progression-free survival was 8.5 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:33.222499+00:00"}
{"study_id": 102290, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to investigate the use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma, not specifically focused on Alanine.", "results_summary": "The study found that perioperative nivolumab did not improve recurrence-free survival compared to surgery alone. Increased alanine aminotransferase was noted as a treatment-related adverse event in the nivolumab group.", "population_specificity": "Patients aged 18+ with high-risk renal cell carcinoma (clinical stage T2 or greater).", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 30.4 months in the nivolumab group.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:33.693172+00:00"}
{"study_id": 102292, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to describe the incidence and types of aberrant hepatic artery and compare differences in TACE outcomes between patients with and without aberrant hepatic artery in HCC treatment.", "results_summary": "The study found a high incidence of aberrant hepatic artery (21.3%) during TACE, with significant differences in operation duration and postoperative nausea/vomiting between groups. Postoperative lab examinations also showed significant differences in liver enzymes and neutrophil percentage.", "population_specificity": "Patients with hepatocellular carcinoma (HCC) who received TACE (mean age 58 \u00b1 10 years, 81.5% male).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:34.995519+00:00"}
{"study_id": 102295, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "To assess the effects of testosterone-based gender affirming hormone therapy on liver blood tests, including alanine-aminotransferase (ALT), in assigned female at birth adults.", "results_summary": "The study found a low prevalence (1%) of biochemical liver damage and transient abnormalities in liver blood tests during testosterone therapy, suggesting minimal liver-related risks.", "population_specificity": "Assigned female at birth adults undergoing testosterone-based gender affirming hormone therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:35.382369+00:00"}
{"study_id": 102294, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers investigated the molecular interaction of cobicistat (a pharmacoenhancer) with the drug-metabolizing enzyme CYP3A4, comparing it to ritonavir.", "results_summary": "The study found that cobicistat coordinates to the heme in CYP3A4 via the thiazole nitrogen, similar to ritonavir, but with 2-fold lower affinity and binding rate (0.030 \u03bcM and 0.72 s).", "population_specificity": "Not specified (molecular-level study).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:35.635012+00:00"}
{"study_id": 102293, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were evaluating the safety and preliminary activity of the SYK inhibitor TAK-659 combined with paclitaxel in patients with advanced taxane-refractory solid tumors, not specifically studying Alanine.", "results_summary": "The study reported increased alanine aminotransferase (ALT) as a common adverse event (53% of patients), but the focus was on the combination therapy's safety and efficacy, not Alanine's effects.", "population_specificity": "Patients with advanced solid tumors and prior progression on taxane-based therapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "28-day cycles (duration not specified for Alanine).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:35.925241+00:00"}
{"study_id": 102297, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether a nutraceutical blend containing bergamot and artichoke extracts could improve lipid profiles, insulin sensitivity, hs-CRP, and NAFLD indexes, including effects on alanine transaminase (ALT).", "results_summary": "The study found significant improvements in lipid profiles (TC, LDL-C, Non-HDL-C, TG), Apo B-100, Apo AI, glucose, ALT, gGT, hs-CRP, NAFLD indexes, and endothelial reactivity in the active-treated group compared to baseline and placebo.", "population_specificity": "90 healthy individuals with suboptimal cholesterol levels.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:41.080666+00:00"}
{"study_id": 102298, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether providing lifestyle intervention (LSI) information via a social media app improved clinical outcomes, including serum alanine aminotransferase (ALT) levels, in MASLD patients compared to standard care.", "results_summary": "The study compared changes in liver steatosis, liver stiffness, weight loss, body composition, and ALT levels between the intervention (social media-based LSI) and control (standard care) groups over 24 weeks, but specific results for ALT or alanine effects were not detailed in the abstract.", "population_specificity": "Noncirrhotic MASLD patients aged 18-65 years in Thailand (median age 53, 64.7% female, median BMI 27.3 kg/m\u00b2).", "effective_dosage": "Not specified (intervention involved infographics sent every 3-7 days).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.541191+00:00"}
{"study_id": 102301, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness of the 15-method in Danish primary care, including the use of biomarkers like Alanine Transaminase, to address alcohol consumption and related problems.", "results_summary": "The abstract does not report specific findings regarding Alanine's effects, focusing instead on the broader 15-method's feasibility and potential benefits for alcohol-related interventions.", "population_specificity": "Patients affiliated with sixteen general practices in the Region of Southern Denmark.", "effective_dosage": "Not specified", "study_duration": "Three-month baseline followed by stepped wedge cluster randomization with varying launch dates.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.727368+00:00"}
{"study_id": 102300, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to study hypoglycemia caused by oral hypoglycemic agents (OHAs), including clinical profiles, medications involved, and outcomes, but did not specifically focus on Alanine.", "results_summary": "The study found that middle-aged females were at higher risk of hypoglycemia due to OHAs, with deranged liver function and raised UPCR associated with higher mortality. Alanine transaminase (ALT/SGPT) was mentioned as a marker of liver function but not as a primary focus.", "population_specificity": "Indoor patients at a tertiary care hospital in Western Maharashtra with hypoglycemic symptoms (blood sugar <70 mg/dL) on OHAs, excluding insulin users.", "effective_dosage": "Not specified", "study_duration": "Data collected over 18 months (study duration, not intervention length).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.774383+00:00"}
{"study_id": 102299, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the quality control efficiency of AI-PBRTQC and traditional PBRTQC for alanine aminotransferase (ALT) and other analytes in clinical laboratories.", "results_summary": "The study found that AI-PBRTQC was more efficient than traditional PBRTQC in identifying quality risks for ALT (10-25), with an optimal parameter setting of \u03bb = 0.02. AI-PBRTQC effectively detected quality risks even with small sample sizes.", "population_specificity": "Patients with ALT and other analyte data over five months in clinical laboratories.", "effective_dosage": "Not specified", "study_duration": "Five months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:44.775764+00:00"}
{"study_id": 102304, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of a precision nutrition strategy, including individualized foods and digital tools, on metabolic health and quality of life in older adults with overweight or obesity, with alanine aminotransferase as one of the measured biomarkers.", "results_summary": "The precision approach significantly improved metabolic health markers, including reductions in alanine aminotransferase levels, alongside improvements in body weight, body fat percentage, and quality of life compared to standard recommendations.", "population_specificity": "127 men and women aged 50-80 years with overweight or obesity.", "effective_dosage": "Not specified", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:45.456998+00:00"}
{"study_id": 102303, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the efficacy of four high-genetic barrier nucleos(t)ide analogues (NAs), including tenofovir disoproxil fumarate (TDF) and entecavir (ETV), in achieving virologic and biochemical responses in chronic hepatitis B (CHB) patients.", "results_summary": "TDF showed superior virologic response (VR) at 48 and 96 weeks compared to ETV, while ETV provided better biochemical response (BR) at 48 weeks. The study included 15,000 patients from 16 studies, confirming these trends in sensitivity analyses.", "population_specificity": "Treatment-na\u00efve chronic hepatitis B (CHB) patients.", "effective_dosage": "Not specified in the abstract.", "study_duration": "48 and 96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:47.168835+00:00"}
{"study_id": 102302, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of garsorasib (D-1553) in patients with KRAS-mutated cancers, focusing on adverse events such as increased liver enzymes (including alanine aminotransferase).", "results_summary": "The study found that garsorasib had a 50% objective response rate but reported frequent treatment-related adverse events, including elevated liver enzymes (alanine aminotransferase in 15% of participants). Most adverse events were manageable, with no new safety signals identified.", "population_specificity": "Adult patients (median age 64) with KRAS-mutated cancers, predominantly male (88%).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Median follow-up of 7.9 months (IQR 6.3-10.4).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:47.200920+00:00"}
{"study_id": 102305, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of ADAMTS-5 inhibition on serum ARGS (Alanine-arginine-glycine-serine) levels and its relationship with cartilage thickness, pain, and function in knee osteoarthritis patients.", "results_summary": "S201086 reduced serum ARGS levels dose-dependently, with maximal reduction at 4 weeks (58.5% for 300 mg), but no association was found between ARGS reduction and changes in cartilage thickness, pain, or function. ARGS levels rebounded post-treatment.", "population_specificity": "Participants with knee osteoarthritis in the ROCCELLA trial.", "effective_dosage": "75, 150, or 300 mg once daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:51.514796+00:00"}
{"study_id": 102307, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a counseling intervention to increase physical activity and reduce sedentary time could improve NAFLD markers, including alanine aminotransferase (ALT) levels, in people with type 2 diabetes.", "results_summary": "The intervention group showed decreased ALT, \u03b3GT, FLI, and HSI levels compared to the control group, with changes correlating with increased physical activity and reduced sedentary time, despite modest increases in moderate-to-vigorous-intensity PA.", "population_specificity": "Physically inactive and sedentary patients with type 2 diabetes.", "effective_dosage": "Not specified (behavioral counseling intervention).", "study_duration": "3 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:54.435050+00:00"}
{"study_id": 102308, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy and safety of nemonoxacin versus levofloxacin for treating community-acquired pneumonia (CAP) in adult patients, not specifically Alanine.", "results_summary": "The study found that nemonoxacin was non-inferior to levofloxacin in clinical cure rates for CAP, with similar microbiological success rates. Adverse events were more frequent with nemonoxacin but mostly mild and resolved after discontinuation.", "population_specificity": "Adult patients with community-acquired pneumonia.", "effective_dosage": "500 mg once daily (nemonoxacin or levofloxacin).", "study_duration": "7-14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:54.479493+00:00"}
{"study_id": 102306, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to predict macrophage activation syndrome (MAS) in children with Kawasaki disease (KD) using clinical and laboratory markers, including alanine transaminase (ALT) levels.", "results_summary": "Elevated ALT levels (>70 U/L) combined with fever duration >5 days were predictive of MAS in children with KD without myocardial dysfunction. Serum albumin levels and fever duration were also significant predictors.", "population_specificity": "Hospitalized children aged 1-18 years with Kawasaki disease (excluding those with COVID-19).", "effective_dosage": "Not specified", "study_duration": "Not specified (cross-sectional observational study from March 2020 - October 2021)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:55.930393+00:00"}
{"study_id": 102309, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the clinical significance of serum CK18-M65 and CK18-M30 levels in patients with chronic hepatitis B (CHB) complicated by nonalcoholic steatohepatitis (NASH) and liver fibrosis, including the role of alanine aminotransferase as a liver function marker.", "results_summary": "Serum CK18-M65 and M30 levels in CHB patients with NASH were positively correlated with liver fibrosis stage, with CK18-M30 showing superior diagnostic efficiency for S2-3 hepatic fibrosis. Alanine aminotransferase was measured as part of liver function indices but was not the primary focus of the study.", "population_specificity": "133 patients with CHB complicated by NASH and 50 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:56.111984+00:00"}
{"study_id": 102310, "supplement_id": 863, "safety_score": "85", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of misoprostol in treating patients with non-alcoholic steatohepatitis (NASH), focusing on liver function tests, inflammatory markers, and metabolic parameters.", "results_summary": "Misoprostol showed significant reductions in liver enzymes (ALT, AST) and steatosis (CAP) compared to placebo, but no improvement in insulin resistance, hepatic fibrosis, or dyslipidemia. IL-6 levels worsened in the placebo group, while remaining stable in the misoprostol group.", "population_specificity": "Patients with NASH, predominantly male (88%), aged 25-64 years, with 38% having type 2 diabetes and 64% being overweight or obese.", "effective_dosage": "200 \u00b5g of misoprostol thrice daily.", "study_duration": "2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:56.629042+00:00"}
{"study_id": 102311, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the predictive value of abnormal liver parameters, including alanine aminotransferase (ALT), in distinguishing gallstone-related acute pancreatitis in HIV-positive and HIV-negative patients.", "results_summary": "Elevated ALT (>100 U/L) and other liver parameters showed high negative predictive value (92-96.7%) for excluding gallstone etiology in HIV-positive patients, but lower predictive value (83.8-84.6%) in HIV-negative patients. Bile duct stones were more frequently found in HIV-positive patients during ERCP.", "population_specificity": "HIV-positive and HIV-negative patients with acute pancreatitis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:57.656413+00:00"}
{"study_id": 102312, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether moderate-intensity aerobic exercise and a traditional Iranian medicine-based diet could regulate ALT and AST enzyme levels in young men.", "results_summary": "The study found that eight weeks of moderate-intensity aerobic exercise and a traditional Iranian medicine-based diet significantly improved ALT and AST regulation in young men (P < .05). The combined intervention group showed the most notable effects.", "population_specificity": "60 young men aged 20-40 years with a cold temperament attending a sports club in Ahvaz, Iran.", "effective_dosage": "Not specified (personalized diet plan and aerobic exercise at 64%-76% of maximum heart rate, 3 sessions/week, 45 minutes each).", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:13:57.865642+00:00"}
{"study_id": 102313, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 60, "study_goal": "The researchers aimed to investigate the effects of liver transplantation on muscle disease progression in a patient with GSD type IIIa, including the role of alanine aminotransferase (ALT) as a marker of muscle involvement.", "results_summary": "The study found that liver transplantation exacerbated muscle disease in GSD type IIIa, with elevated ALT and AST levels attributed to muscle involvement. A high-protein, ketogenic diet did not significantly improve myalgia.", "population_specificity": "A 31-year-old man with GSD type IIIa and end-stage liver disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:01.750279+00:00"}
{"study_id": 102315, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review recent developments in dosimetry for FLASH radiotherapy, focusing on standard instruments and protocols for clinical implementation.", "results_summary": "The abstract summarizes advancements in dosimetry standards and procedures for FLASH radiotherapy but does not mention Alanine or its effects.", "population_specificity": "Not specified (focus is on dosimetry for FLASH radiotherapy).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:02.379889+00:00"}
{"study_id": 102314, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether alanine levels, along with other metabolites, were associated with 6-month mortality in out-of-hospital cardiac arrest (OHCA) patients receiving targeted temperature management with or without xenon.", "results_summary": "Increased alanine levels at 72 hours were associated with higher 6-month mortality in OHCA patients. The study found no significant metabolic differences between the xenon and control groups regarding alanine.", "population_specificity": "Out-of-hospital cardiac arrest survivors (n=110) receiving targeted temperature management.", "effective_dosage": "Not specified for alanine (study focused on metabolic profiling, not supplementation).", "study_duration": "Blood samples were drawn upon admission, at 24, and 72 hours.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:05.114687+00:00"}
{"study_id": 102317, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the risk of adverse events (AEs) related to EGFR-TKIs, including elevated alanine aminotransferase, in patients with non-small cell lung cancer.", "results_summary": "The study found that EGFR-TKIs significantly increased the risk of elevated alanine aminotransferase (a hepatic AE), with an odds ratio of 3.93 for high-grade events. Gefitinib, in particular, was associated with hepatotoxicity.", "population_specificity": "Patients with EGFR-mutant non-small cell lung cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:05.900218+00:00"}
{"study_id": 102318, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not studying Alanine; the abstract focuses on Silymarin's effects on \u03b2-thalassemia outcomes in children and adolescents.", "results_summary": "The abstract does not mention Alanine or its effects.", "population_specificity": "Children and adolescents with \u03b2-thalassemia.", "effective_dosage": "Not mentioned for Alanine.", "study_duration": "Not mentioned for Alanine.", "interactions": "None mentioned for Alanine.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:05.931459+00:00"}
{"study_id": 102320, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of oral contraceptive (OC) and spiomet treatments on liver enzymes (including ALT) and organokine levels in adolescent girls with PCOS.", "results_summary": "OC treatment increased ALT and GGT levels, which returned to baseline post-treatment, while spiomet treatment showed no changes in ALT levels. ALT levels correlated with METRNL levels only in OC-treated girls.", "population_specificity": "Adolescent girls with PCOS and without obesity.", "effective_dosage": "Not specified for alanine (ALT was measured as a biomarker, not administered).", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:07.406091+00:00"}
{"study_id": 102316, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify mechanisms and predictive biomarkers for persistently elevated alanine aminotransferase (ALT) in chronic hepatitis B (CHB) patients after complete viral suppression.", "results_summary": "The study identified specific metabolites, including Ser-Phe-Ala and Lys-Ala-Leu-Glu, as potential biomarkers for elevated ALT risk. N-acetyl-l-methionine (NALM) supplementation was found to alleviate liver injury in mice.", "population_specificity": "Patients with chronic hepatitis B (CHB) who achieved complete viral suppression after antiviral treatment.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 2.42 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:07.580819+00:00"}
{"study_id": 102319, "supplement_id": 863, "safety_score": "85", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the long-term safety and tolerability of fezolinetant, a nonhormonal neurokinin 3 receptor antagonist, among Chinese women with vasomotor symptoms associated with menopause.", "results_summary": "The study found that fezolinetant 30 mg once daily was generally safe and well tolerated over 52 weeks, with most treatment-emergent adverse events being mild or moderate. No clinically relevant changes in endometrial thickness or Hy's Law cases were reported.", "population_specificity": "Chinese women aged 40-65 years with vasomotor symptoms associated with menopause.", "effective_dosage": "30 mg once daily", "study_duration": "52 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:07.777717+00:00"}
{"study_id": 102322, "supplement_id": 863, "safety_score": "90", "efficacy_score": 50, "quality_score": 85, "study_goal": "The researchers aimed to assess the tolerability and safety of glutamine supplementation in older adults, focusing on its potential as a well-tolerated intervention for maintaining health.", "results_summary": "The study found that oral glutamine supplementation did not induce significant changes in any evaluated parameters, including inflammatory markers and growth factors, and no adverse effects were reported, suggesting it was well-tolerated and safe.", "population_specificity": "Older adults (mean ages 77.0\u00b19.1 and 79.0\u00b16.9 years) recruited from three daycare centers.", "effective_dosage": "12.4 g of oral effervescent glutamine daily.", "study_duration": "60 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:12.518529+00:00"}
{"study_id": 102321, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the association of TAS2R38 polymorphisms (including the PAV allele containing Alanine) with bitter taste phenotypes and their links to alcohol consumption and smoking behavior.", "results_summary": "The study found that the TAS2R38 taster genotype (PAV allele) was significantly associated with bitter taste sensitivity (OR, 5.88; CI [3.87, 8.95]), suggesting a strong genetic influence on taste perception related to alcohol and smoking.", "population_specificity": "Individuals with varying bitter taste sensitivity, including those who drink alcohol and smokers.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:12.861757+00:00"}
{"study_id": 102323, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to analyze the effect of ipragliflozin on alanine transaminase (ALT) levels in patients with type 2 diabetes mellitus (T2DM).", "results_summary": "The meta-analysis found that ipragliflozin as a monotherapy significantly reduced ALT levels at week 12 compared to the control group, suggesting beneficial effects on liver enzymes. Further large-scale RCTs are needed to confirm its role in liver-related conditions in T2DM.", "population_specificity": "Patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:14.883275+00:00"}
{"study_id": 102325, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess immune responses related to AAV5-capsid and transgene-derived FVIII-specific effects, including potential correlations with alanine aminotransferase elevations, following valoctocogene roxaparvovec administration.", "results_summary": "The study found no FVIII inhibitors post-treatment, with immune responses primarily directed at the AAV5 capsid. Alanine aminotransferase elevations were weakly correlated with AAV5-specific cellular immune responses but showed no association with FVIII activity changes.", "population_specificity": "134 adult men with severe hemophilia A", "effective_dosage": "Not specified", "study_duration": "2 years of follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:15.969337+00:00"}
{"study_id": 102324, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the epidemiologic and comorbidity profiles of patients with chronic Hepatitis D (CHD) and explore their interferon (IFN) eligibility, including the role of elevated alanine transaminase (ALT) as a marker.", "results_summary": "The study found that anti-HDV positive patients, including those with elevated ALT, were more likely to have cirrhosis or hepatocellular carcinoma (HCC). Extrahepatic comorbidities were common and impacted IFN therapy eligibility.", "population_specificity": "HBsAg-positive patients in Italy, including both Italians and non-Italians, with a focus on those with chronic Hepatitis D (CHD).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:16.162472+00:00"}
{"study_id": 102327, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether FIB-4 could effectively screen and monitor changes in steatohepatitis (MASH) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).", "results_summary": "FIB-4 correlated with histological MASLD activity scores (NAS), particularly cellular ballooning, and changes in FIB-4 were associated with changes in NAS. Pioglitazone and vitamin E improved NAS and histological sub-scores for steatosis and inflammation, but not fibrosis grade.", "population_specificity": "Adult patients without diabetes mellitus and with MASLD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:17.394747+00:00"}
{"study_id": 102328, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of Qushi Huayu (QSHY) on liver fat content and serum alanine aminotransferase (ALT) levels in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "QSHY treatment significantly improved ALT levels, aspartate transaminase levels, and fibrosis-4 scores compared to DFLG. It also improved gut dysbiosis, with changes in microbial abundance linked to ALT reduction.", "population_specificity": "246 patients with NAFLD and liver dysfunction.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:17.426234+00:00"}
{"study_id": 102326, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a population pharmacokinetic model for ZSP1601 and investigate exposure-response relationships related to efficacy and safety, focusing on its effects on ALT, AST, and LFC in NAFLD patients.", "results_summary": "The study found that ZSP1601's pharmacokinetics were best described by a two-compartment model, with body weight and food consumption influencing its profile. Exposure-response analysis showed significant relationships between ZSP1601 exposure and improvements in ALT, AST, and LFC.", "population_specificity": "Healthy volunteers and NAFLD patients (95 subjects total).", "effective_dosage": "100 mg twice daily (proposed for subsequent trials).", "study_duration": "Not specified in the abstract.", "interactions": "Food consumption (FED) influenced absorption rate constant and duration.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:18.273695+00:00"}
{"study_id": 102330, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the association between serum HBV DNA levels and HCC risk in CHB patients, arguing for antiviral treatment decisions based on HBV DNA levels rather than ALT levels.", "results_summary": "The study found that HCC risk is significantly associated with serum HBV DNA levels in a non-linear parabolic manner, regardless of ALT levels or HBeAg status, suggesting antiviral treatment should prioritize HBV DNA levels over ALT.", "population_specificity": "Chronic hepatitis B virus (HBV) infection (CHB) patients, both untreated and treated.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:21.871834+00:00"}
{"study_id": 102329, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 68, "study_goal": "The researchers aimed to evaluate the effects of stage-based care on patients with chronic HBV infection, including monitoring alanine transaminase levels as part of blood biochemical indices.", "results_summary": "Stage-based care improved patient satisfaction, reduced pain and depression scores, and enhanced blood biochemical indices, including alanine transaminase levels, compared to general care.", "population_specificity": "156 patients with chronic HBV infection (experimental group) and 144 patients with chronic HBV infection (control group).", "effective_dosage": "Not specified", "study_duration": "September 2018 to December 2019 (experimental group), January 2018 to August 2018 (control group)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:22.119669+00:00"}
{"study_id": 102331, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of pemafibrate and omega-3-acid ethyl ester on hepatic function, specifically focusing on alanine aminotransferase (ALT) levels, in patients with hypertriglyceridemia complicated by MASLD.", "results_summary": "Pemafibrate significantly reduced ALT levels compared to omega-3-acid ethyl ester, improved other hepatic enzymes, lipid profiles, and hepatic fibrosis biomarkers, with no safety concerns or discontinuations due to adverse reactions.", "population_specificity": "Patients with hypertriglyceridemia complicated by MASLD.", "effective_dosage": "Not specified in the abstract.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:24.735968+00:00"}
{"study_id": 102333, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the efficacy of stem cell therapy in improving liver function, including changes in alanine aminotransferase levels, in chronic liver disease patients.", "results_summary": "The study found a significant decrease in alanine aminotransferase levels (SMD: -0.499), indicating potential hepatoprotective effects of stem cell therapy. No significant changes were observed in total bilirubin levels or Model for End-Stage Liver Disease scores in randomized controlled trials.", "population_specificity": "Chronic liver disease patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:25.266564+00:00"}
{"study_id": 102332, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the antioxidant and protective effects of aqueous oak (Quercus brantii) extract supplementation, including its impact on alanine transferase levels, in \u03b2-thalassemia major patients.", "results_summary": "The study found no significant changes in serum alanine transferase levels after Quercus extract supplementation, though it significantly reduced oxidative stress markers (MDA, protein CO) and increased antioxidant capacity (TAC, SOD).", "population_specificity": "60 major \u03b2-thalassemia patients.", "effective_dosage": "300 mg/day of aqueous Quercus extract capsules.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:25.811614+00:00"}
{"study_id": 102334, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the existing data on semaglutide's effects, including its impact on alanine aminotransferase levels, in adolescents with obesity.", "results_summary": "Semaglutide improved elevated alanine aminotransferase levels and other metabolic parameters in youth with obesity, but long-term safety data, including risks like pancreatitis and disordered eating, remain limited.", "population_specificity": "Adolescents with obesity", "effective_dosage": "Once weekly subcutaneous injection (specific dosage not mentioned)", "study_duration": "68 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:26.498123+00:00"}
{"study_id": 102335, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether hepatic function markers, including total bilirubin, could predict mortality in patients undergoing continuous renal replacement therapy (CRRT).", "results_summary": "The study found that total bilirubin levels 3 days after CRRT initiation could stratify mortality risk, with higher bilirubin levels associated with increased 90-day mortality (34.7%). Propensity score matching supported a cutoff of 1.2 mg/dL for risk prediction.", "population_specificity": "1,899 CRRT patients with acute kidney injury secondary to cardiovascular disease or sepsis.", "effective_dosage": "Not applicable", "study_duration": "Follow-up until 90 days after CRRT initiation", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:27.332299+00:00"}
{"study_id": 102336, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "To assess the clinical value of seven non-invasive models, including those involving alanine transaminase (ALT), as alternatives to liver biopsy for diagnosing high-risk MASH.", "results_summary": "FIB-4 and FAST showed better diagnostic efficacy for high-risk MASH compared to other models, with FAST being superior. S index and GPR exhibited almost no diagnostic value.", "population_specificity": "309 patients diagnosed with NAFLD, with 279 in the overall population and 117 in the FibroScan subgroup.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:28.210149+00:00"}
{"study_id": 102337, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of GDF15, including its relationship with molecules of the alanine cycle, in obesity and MASLD, focusing on fasting and stimulated levels during metabolic tests.", "results_summary": "The study found that postprandial GDF15 levels clustered with triglycerides and molecules of the alanine cycle, showing robust elevation in MASLD patients compared to controls, suggesting a potential role in MASLD pathophysiology.", "population_specificity": "Adults with normal weight or obesity (Study 1) and adults with MASLD or healthy controls (Study 2).", "effective_dosage": "Not specified", "study_duration": "Study 1: 3-hour mixed meal test; Study 2: 120-minute oral glucose tolerance test.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:32.694674+00:00"}
{"study_id": 102340, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it focuses on bulevirtide (BLV) for chronic hepatitis delta (CHD).", "results_summary": "The study does not provide results related to Alanine.", "population_specificity": "Patients with chronic hepatitis delta (CHD) (N = 150).", "effective_dosage": "Not applicable (Alanine not studied).", "study_duration": "Not applicable (Alanine not studied).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:33.310810+00:00"}
{"study_id": 102338, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the therapeutic effectiveness of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in treating chronic hepatitis B (CHB), including their impact on liver function markers like alanine aminotransferase (ALT).", "results_summary": "Both TAF and TDF improved liver function (ALT, AST, TBIL) and achieved similar clinical cure rates, but TAF had fewer adverse reactions. Cost-effectiveness was comparable despite TAF being more expensive.", "population_specificity": "241 chronic hepatitis B patients (180 in TAF group, 61 in TDF group).", "effective_dosage": "Not specified", "study_duration": "Treatment period from January 2020 to December 2021 (exact duration per patient unclear).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:33.660154+00:00"}
{"study_id": 102343, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effect of a synbiotic intervention on liver metabolism, specifically focusing on alanine aminotransferase (ALT) levels in metabolically healthy males.", "results_summary": "The study found a significant reduction in ALT levels (-14.92%) in the synbiotic group compared to the placebo group after seven weeks, indicating potential benefits for liver metabolism.", "population_specificity": "117 metabolically healthy male participants", "effective_dosage": "Not specified", "study_duration": "7 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:35.668410+00:00"}
{"study_id": 102339, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the prognostic performance of non-invasive biomarkers, including alanine aminotransferase (ALT), in NASH cirrhosis and evaluate their utility as treatment monitoring biomarkers.", "results_summary": "The study identified ALT as part of the BARD score and liver enzymes (AST + ALT) among non-invasive biomarkers with prognostic value in NASH patients, but did not specifically evaluate alanine's standalone effects.", "population_specificity": "Patients with nonalcoholic steatohepatitis (NASH) cirrhosis or NAFLD with a focus on cirrhosis.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:35.859031+00:00"}
{"study_id": 102342, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of alanine and other metabolites in the neurological alterations associated with GDM and T2DM, focusing on DNA damage and neurotransmitter changes.", "results_summary": "The study found that alanine, along with tyrosine, carbon metabolites, aspartate, and glutamate, were signature metabolites altered in both GDM and T2DM populations, suggesting a potential role in neurological injury. These changes were linked to DNA damage markers and neurotransmitter alterations.", "population_specificity": "Patients with gestational diabetes mellitus (GDM) and type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:36.209687+00:00"}
{"study_id": 102341, "supplement_id": 863, "safety_score": "70", "efficacy_score": 60, "quality_score": 65, "study_goal": "The researchers investigated the effects of oral iron supplementation on PPIX levels and related outcomes, including plasma alanine transaminase, in EPP patients with iron deficiency.", "results_summary": "Iron supplementation led to increased PPIX levels in most patients, a rise in ferritin, and improved hemoglobin in anemic patients, but also caused a transient elevation in plasma alanine transaminase.", "population_specificity": "Patients with erythropoietic protoporphyria (EPP) and iron deficiency (10 participants).", "effective_dosage": "330 mg of ferrous fumarate daily.", "study_duration": "2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:36.315316+00:00"}
{"study_id": 102344, "supplement_id": 863, "safety_score": "65", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of cotadutide, a GLP-1/GCG receptor co-agonist, in improving liver health markers like alanine aminotransferase (ALT) and metabolic parameters in patients with noncirrhotic MASH and fibrosis.", "results_summary": "The study found dose- and time-dependent improvements in ALT and other liver health markers, with significant reductions in ALT (-23.5 U/L) and AST (-16.8 U/L) at the 600 \u03bcg dose. Adverse events were common but mostly mild to moderate gastrointestinal effects, with higher discontinuation rates at the higher dose.", "population_specificity": "74 participants with biopsy-proven noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis.", "effective_dosage": "600 \u03bcg and 300 \u03bcg cotadutide.", "study_duration": "19 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:40.639030+00:00"}
{"study_id": 102347, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the protective effect of early-initiated N-AC therapy on liver toxicity in pediatric acetaminophen poisoning cases, with a focus on alanine aminotransferase values.", "results_summary": "The study found that early N-AC treatment within 8 hours reduced liver toxicity risk by 43 times, while elevated alanine aminotransferase (>1000 U/L) significantly increased liver transplantation risk.", "population_specificity": "Pediatric cases of acetaminophen poisoning.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:42.664662+00:00"}
{"study_id": 102345, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of therapeutic plasma exchange (TPE) alone or combined with continuous venovenous hemodiafiltration (CVVHDF) in treating liver failure in pediatric patients, focusing on biochemical markers including alanine aminotransferase.", "results_summary": "The study found significant reductions in alanine aminotransferase levels (from 1255 to 148 in the TPE-only group and from 1749 to 1148 in the TPE+CVVHDF group), indicating improved liver function. Both treatment approaches showed statistically significant improvements, with 58% transplant-free survival.", "population_specificity": "Pediatric patients aged 1 month to 18 years with acute liver failure or acute-chronic liver failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:44.630721+00:00"}
{"study_id": 102349, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate clinical predictors for choledocholithiasis, including alanine aminotransferase levels, and establish Korean-specific cutoff values and a predictive model.", "results_summary": "The study established a Korean cutoff value for alanine aminotransferase (>26.5 U/L) as a predictor for choledocholithiasis, but it was not significant in the multivariate analysis. The new risk stratification model performed moderately (AUC 0.777).", "population_specificity": "Patients who underwent laparoscopic cholecystectomy in a Korean clinical context.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:45.277421+00:00"}
{"study_id": 102350, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to evaluate biomarkers of mitochondrial dysfunction, including alanine, in individuals with autism spectrum disorder (ASD).", "results_summary": "The study found a significant elevation (15%, p < 0.01) in alanine levels in individuals with ASD compared to controls, suggesting a potential association with mitochondrial dysfunction. Alanine was also linked to clinical features such as delays in language, social interaction, and motor skills, though not all studies found consistent associations.", "population_specificity": "Individuals with autism spectrum disorder (ASD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:45.590506+00:00"}
{"study_id": 102351, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the risk of laboratory abnormalities in acne patients treated with isotretinoin versus oral antibiotics, including effects on alanine transaminase (ALT) levels.", "results_summary": "The study found no significant risk of grade \u22653 impairment in alanine transaminase (ALT) levels under isotretinoin treatment. Most laboratory abnormalities occurred 1-3 months after drug initiation.", "population_specificity": "Patients with acne prescribed isotretinoin (n=79,012) or oral antibiotics (n=79,012).", "effective_dosage": "Not specified", "study_duration": "Initial 3 months of treatment, with follow-up for abnormalities.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:46.002645+00:00"}
{"study_id": 102346, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety, optimal dosing, and efficacy of lurbinectedin plus doxorubicin in patients with advanced/metastatic soft-tissue sarcoma, including monitoring alanine aminotransferase (ALT) levels as part of toxicity assessment.", "results_summary": "The study reported reversible dose-limiting toxicities, including grade 2 and 3 ALT increases, but all patients continued treatment. The combination showed promising clinical activity with a 60% objective response rate and median progression-free survival of 16.5 months.", "population_specificity": "Patients with advanced/metastatic soft-tissue sarcoma and no prior anthracycline/lurbinectedin/trabectedin exposure.", "effective_dosage": "Lurbinectedin 3.2 mg/m\u00b2 (day 1) plus doxorubicin 25 mg/m\u00b2 (day 1 or days 1 and 8) every 3 weeks.", "study_duration": "3-week cycles, with data cutoff at 6 months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:47.092333+00:00"}
{"study_id": 102348, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of laparoscopic-assisted microwave ablation (LAMWA) and laparoscopic hepatectomy in treating small hepatocellular carcinoma (HCC), including liver function recovery as measured by alanine transaminase (ALT) levels.", "results_summary": "The study found that LAMWA resulted in lower peak ALT and AST levels, shorter operation times, less blood loss, and shorter hospital stays compared to laparoscopic hepatectomy, with comparable long-term survival rates.", "population_specificity": "140 patients with small HCC (68 in LAMWA group, 72 in hepatectomy group).", "effective_dosage": "Not available", "study_duration": "Follow-up included one-, three-, and five-year survival rates.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T09:14:47.364029+00:00"}
